

Hagop M Kantarjian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3309298/publications.pdf>

Version: 2024-02-01

1,401
papers

157,609
citations

51

182
h-index

114

342
g-index

1438
all docs

1438
docs citations

1438
times ranked

53405
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2001, 344, 1031-1037.	13.9	4,825
2	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 994-1004.	13.9	3,227
3	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2006, 355, 2408-2417.	13.9	3,212
4	Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. <i>New England Journal of Medicine</i> , 2001, 344, 1038-1042.	13.9	2,593
5	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 2454-2465.	0.6	2,458
6	Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2002, 346, 645-652.	13.9	1,899
7	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
8	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 799-807.	13.9	1,738
9	Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias. <i>New England Journal of Medicine</i> , 2006, 354, 2531-2541.	13.9	1,606
10	Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2251-2259.	13.9	1,497
11	Decitabine improves patient outcomes in myelodysplastic syndromes. <i>Cancer</i> , 2006, 106, 1794-1803.	2.0	1,447
12	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2011, 364, 2496-2506.	13.9	1,444
13	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	13.9	1,443
14	Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2260-2270.	13.9	1,411
15	Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. <i>Blood</i> , 2006, 108, 419-425.	0.6	1,395
16	Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. <i>Blood</i> , 2019, 133, 7-17.	0.6	1,254
17	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL. <i>New England Journal of Medicine</i> , 2006, 354, 2542-2551.	13.9	1,253
18	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211

#	ARTICLE	IF	CITATIONS
19	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	0.8	1,188
20	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006, 108, 1809-1820.	0.6	1,184
21	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.	0.6	1,173
22	The Biology of Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1999, 341, 164-172.	13.9	1,126
23	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , 2018, 378, 2386-2398.	13.9	1,092
24	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 740-753.	13.9	1,047
25	Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. <i>New England Journal of Medicine</i> , 2010, 363, 1117-1127.	13.9	1,046
26	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66.	5.1	1,031
27	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2670-2677.	0.8	998
28	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002, 99, 1928-1937.	0.6	943
29	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 917-927.	13.9	926
30	Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4079-4088.	0.8	899
31	Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. <i>Cancer Discovery</i> , 2016, 6, 1106-1117.	7.7	799
32	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. <i>Blood</i> , 2004, 103, 1635-1640.	0.6	783
33	United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 3852-3860.	0.8	773
34	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2333-2340.	0.8	724
35	Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 547-547.	0.8	706
36	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. <i>Blood</i> , 2007, 110, 3540-3546.	0.6	688

#	ARTICLE	IF	CITATIONS
37	Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon Alpha_A in Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 1986, 314, 1065-1069.	13.9	683
38	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Blood</i> , 2007, 109, 52-57.	0.6	675
39	Ponatinib in Refractory Philadelphia Chromosomeâ€“Positive Leukemias. <i>New England Journal of Medicine</i> , 2012, 367, 2075-2088.	13.9	668
40	Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2004, 103, 3669-3676.	0.6	593
41	Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 2165-2170.	0.8	572
42	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. <i>Blood</i> , 2007, 109, 2303-2309.	0.6	563
43	Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2014, 4, 362-375.	7.7	561
44	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2018, 19, 216-228.	5.1	551
45	Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Cancer</i> , 2004, 101, 2788-2801.	2.0	550
46	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:. <i>Cancer</i> , 2006, 106, 1090-1098.	2.0	550
47	The financial burden and distress of patients with cancer: Understanding and steppingâ€“up action on the financial toxicity of cancer treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 153-165.	157.7	542
48	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i> , 2004, 103, 4396-4407.	0.6	522
49	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2012, 119, 1123-1129.	0.6	520
50	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i> , 2006, 106, 1569-1580.	2.0	503
51	Phase 1/2 study of the combination of 5-aza-2â€“deoxycytidine with valproic acid in patients with leukemia. <i>Blood</i> , 2006, 108, 3271-3279.	0.6	492
52	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. <i>Blood</i> , 2014, 124, 2705-2712.	0.6	486
53	Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4070-4078.	0.8	480
54	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. <i>Cancer</i> , 2008, 113, 1351-1361.	2.0	458

#	ARTICLE	IF	CITATIONS
55	Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 3204-3212.	0.8	458
56	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. <i>Lancet Oncology</i> , The, 2011, 12, 841-851.	5.1	444
57	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 303-309.	0.6	441
58	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	0.6	440
59	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2012, 30, 3376-3382.	0.8	419
60	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-â€“positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. <i>Blood</i> , 2011, 118, 4567-4576.	0.6	406
61	Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3486-3492.	0.8	404
62	Inotuzumab ozogamicin, an anti-CD22â€“calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 403-411.	5.1	401
63	Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-â€“ Therapy. <i>Annals of Internal Medicine</i> , 1995, 122, 254.	2.0	394
64	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	0.6	393
65	Ponatinib efficacy and safety in Philadelphia chromosome-â€“positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	0.6	392
66	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. <i>Blood</i> , 2007, 110, 2302-2308.	0.6	391
67	Targeting DNA Methylation. <i>Clinical Cancer Research</i> , 2009, 15, 3938-3946.	3.2	388
68	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	13.9	388
69	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	9.4	384
70	Chronic Myelogenous Leukemia: Biology and Therapy. <i>Annals of Internal Medicine</i> , 1999, 131, 207.	2.0	382
71	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	7.7	380
72	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i> , 2006, 107, 3469-3473.	0.6	371

#	ARTICLE	IF	CITATIONS
73	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome ⁺ positive chronic phase chronic myeloid leukemia. <i>Blood</i> , 2004, 103, 2873-2878.	0.6	369
74	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2014, 123, 494-500.	0.6	364
75	MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. <i>Blood</i> , 2007, 109, 500-502.	0.6	363
76	Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome ⁻ Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3880-3889.	0.8	361
77	Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. <i>Blood</i> , 2002, 99, 840-849.	0.6	356
78	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. <i>Blood</i> , 2007, 109, 5143-5150.	0.6	356
79	Effective Treatment of Acute Promyelocytic Leukemia With All- <i>Trans</i> -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. <i>Journal of Clinical Oncology</i> , 2009, 27, 504-510.	0.8	355
80	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013, 121, 4655-4662.	0.6	355
81	Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications. <i>Annals of Internal Medicine</i> , 2001, 134, 573.	2.0	351
82	Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. <i>Journal of Clinical Oncology</i> , 2007, 25, 3908-3914.	0.8	350
83	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1856-1862.	0.8	347
84	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011, 117, 1141-1145.	0.6	344
85	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , 2010, 116, 4422-4429.	0.6	336
86	Clinical experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	2.0	336
87	DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2010, 28, 605-613.	0.8	327
88	High Frequency and Poor Outcome of Philadelphia Chromosome ⁻ Like Acute Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2017, 35, 394-401.	0.8	326
89	Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 1414-1420.	0.8	321
90	Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3842-3848.	0.8	321

#	ARTICLE	IF	CITATIONS
91	Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3â€™Internal Tandem Duplication Status. <i>Journal of Clinical Oncology</i> , 2013, 31, 3681-3687.	0.8	321
92	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosomeâ€™positive (Ph+) acute lymphoblastic leukemia. <i>Blood</i> , 2010, 116, 2070-2077.	0.6	319
93	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	0.6	317
94	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1090-1099.	5.1	315
95	Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. <i>Blood</i> , 2003, 102, 2379-2386.	0.6	313
96	Acute myeloid leukemia: current progress and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 41.	2.8	313
97	Myelodysplastic syndromes: the complexity of stem-cell diseases. <i>Nature Reviews Cancer</i> , 2007, 7, 118-129.	12.8	311
98	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. <i>Blood</i> , 2003, 101, 473-475.	0.6	304
99	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 4679-4685.	0.6	303
100	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood</i> , 2015, 125, 2062-2067.	0.6	303
101	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. <i>Journal of Hematology and Oncology</i> , 2017, 10, 55.	6.9	302
102	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , 2012, 119, 1981-1987.	0.6	298
103	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. <i>Lancet Oncology</i> , The, 2017, 18, 100-111.	5.1	296
104	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	7.7	292
105	Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. <i>American Journal of Hematology</i> , 2018, 93, 442-459.	2.0	291
106	Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate. <i>Journal of Clinical Oncology</i> , 2005, 23, 3948-3956.	0.8	290
107	Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998, 91, 3995-4019.	0.6	287
108	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, 11589.	5.8	285

#	ARTICLE	IF	CITATIONS
109	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. <i>Blood</i> , 2017, 129, 572-581.	0.6	285
110	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. <i>Blood</i> , 2007, 110, 4005-4011.	0.6	284
111	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008, 111, 1834-1839.	0.6	284
112	Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase. <i>Blood</i> , 2002, 99, 3547-3553.	0.6	282
113	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. <i>Blood</i> , 2012, 119, 3403-3412.	0.6	281
114	Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i> -Mutant Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1584-1594.	0.8	278
115	Cancer Drugs in the United States: <i>Justum Pretium</i> —The Just Price. <i>Journal of Clinical Oncology</i> , 2013, 31, 3600-3604.	0.8	276
116	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. <i>New England Journal of Medicine</i> , 2019, 380, 1628-1637.	13.9	274
117	Flying under the radar: the new wave of BCR–ABL inhibitors. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 834-848.	21.5	272
118	Chronic myelogenous leukemia in blast crisis. <i>American Journal of Medicine</i> , 1987, 83, 445-454.	0.6	270
119	Discontinuation of imatinib therapy after achieving a molecular response. <i>Blood</i> , 2004, 104, 2204-2205.	0.6	270
120	Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. <i>American Journal of Medicine</i> , 1990, 88, 1-8.	0.6	268
121	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <i>Blood</i> , 2020, 135, 463-471.	0.6	266
122	Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 424-430.	0.8	265
123	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 2728-2736.	2.0	265
124	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. <i>Blood</i> , 2019, 133, 676-687.	0.6	262
125	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 127-140.	21.5	261
126	Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics. <i>Annals of Internal Medicine</i> , 2003, 138, 819.	2.0	259

#	ARTICLE	IF	CITATIONS
127	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019, 12, 1.	6.9	257
128	Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2005, 11, 3425-3432.	3.2	256
129	DNA Methylation Changes after 5-Aza-2-Deoxycytidine Therapy in Patients with Leukemia. <i>Cancer Research</i> , 2006, 66, 5495-5503.	0.4	253
130	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. <i>Blood</i> , 2016, 127, 1863-1869.	0.6	253
131	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1099-1110.	5.1	249
132	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. <i>Haematologica</i> , 2015, 100, 479-488.	1.7	246
133	Characteristics of accelerated disease in chronic myelogenous leukemia. <i>Cancer</i> , 1988, 61, 1441-1446.	2.0	245
134	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 1547-1555.	5.1	245
135	Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1542-1551.	3.0	243
136	Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2012, 118, 3123-3127.	2.0	243
137	Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 1999, 17, 2461-2461.	0.8	242
138	Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. <i>American Journal of Hematology</i> , 2015, 90, 732-736.	2.0	242
139	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. <i>Cancer</i> , 2010, 116, 3830-3834.	2.0	241
140	Congestive heart failure is a rare event in patients receiving imatinib therapy. <i>Blood</i> , 2007, 110, 1233-1237.	0.6	233
141	Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 2521-2527.	0.8	232
142	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i> , 2004, 104, 1624-1630.	0.6	231
143	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. <i>Journal of Clinical Oncology</i> , 2010, 28, 392-397.	0.8	231
144	Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. <i>Haematologica</i> , 2010, 95, 232-240.	1.7	231

#	ARTICLE	IF	CITATIONS
145	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. <i>Blood</i> , 2014, 123, 1353-1360.	0.6	231
146	Results of decitabine (5-aza-2'-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. <i>Cancer</i> , 2003, 98, 522-528.	2.0	230
147	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. <i>Blood</i> , 2008, 112, 981-989.	0.6	229
148	Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. <i>American Journal of Hematology</i> , 2020, 95, 691-709.	2.0	229
149	Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. <i>Blood</i> , 2004, 103, 784-789.	0.6	228
150	Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 398-404.	0.8	227
151	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> , 2015, 2, e186-e193.	2.2	227
152	Adult acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 1165-1176.	2.0	225
153	The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. <i>British Journal of Haematology</i> , 2006, 135, 165-173.	1.2	223
154	The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2007, 136, 624-627.	1.2	223
155	Complete cytogenetic and molecular responses to interferon- γ -based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. <i>Cancer</i> , 2003, 97, 1033-1041.	2.0	219
156	Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i> 1997, 90, 2969-2977.	0.6	218
157	New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance. <i>Annals of Internal Medicine</i> , 2006, 145, 913.	2.0	216
158	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. <i>Blood</i> , 2003, 101, 3794-3800.	0.6	215
159	Acute promyelocytic leukemia. <i>American Journal of Medicine</i> , 1986, 80, 789-797.	0.6	214
160	The incidence and impact of thrombocytopenia in myelodysplastic syndromes. <i>Cancer</i> , 2007, 109, 1705-1714.	2.0	214
161	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 612-621.	5.1	214
162	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017, 129, 1275-1283.	0.6	214

#	ARTICLE	IF	CITATIONS
163	Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. <i>Blood</i> , 2005, 105, 940-947.	0.6	213
164	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. <i>Blood</i> , 2003, 101, 1692-1697.	0.6	210
165	Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia. <i>Cancer Research</i> , 2004, 64, 672-677.	0.4	210
166	Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib. <i>Journal of Clinical Oncology</i> , 2006, 24, 1204-1208.	0.8	210
167	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. <i>Cancer</i> , 2019, 125, 2474-2487.	2.0	210
168	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. <i>Nature Communications</i> , 2020, 11, 5327.	5.8	208
169	Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia. <i>Cancer Control</i> , 2009, 16, 122-131.	0.7	207
170	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2020, 6, 1890.	3.4	207
171	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet, The</i> , 2020, 396, 1885-1894.	6.3	206
172	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. <i>Blood</i> , 2012, 120, 1202-1209.	0.6	205
173	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2018, 19, 889-903.	5.1	205
174	Survival benefit with imatinib mesylate versus interferon- γ -based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. <i>Blood</i> , 2006, 108, 1835-1840.	0.6	204
175	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. <i>Haematologica</i> , 2015, 100, 1139-1145.	1.7	203
176	AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 4941-4947.	3.2	202
177	Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors. <i>Journal of Clinical Oncology</i> , 2010, 28, 549-555.	0.8	202
178	Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin \pm All-Trans Retinoic Acid \pm Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 1999, 93, 2478-2484.	0.6	201
179	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology, the</i> , 2020, 7, e724-e736.	2.2	201
180	New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 2517-2528.	2.0	200

#	ARTICLE	IF	CITATIONS
181	<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491.	2.0	200
182	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood</i> , 2008, 112, 1638-1645.	0.6	199
183	Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias. <i>Clinical Cancer Research</i> , 2004, 10, 3371-3376.	3.2	195
184	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- α treatment. <i>Blood</i> , 2008, 111, 1039-1043.	0.6	195
185	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. <i>Cancer</i> , 2009, 115, 4136-4147.	2.0	195
186	Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2016, 128, 504-507.	0.6	194
187	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2012, 120, 4840-4845.	0.6	193
188	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , 2018, 19, 240-248.	5.1	192
189	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 653-661.	1.7	191
190	Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. <i>Blood</i> , 2013, 122, 1214-1221.	0.6	190
191	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e618-e627.	2.2	190
192	Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. <i>Blood</i> , 2012, 119, 4480-4485.	0.6	189
193	Evolution of decitabine development. <i>Cancer</i> , 2008, 112, 2341-2351.	2.0	187
194	Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1766-1771.	0.8	187
195	Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers. <i>Journal of Clinical Oncology</i> , 2003, 21, 1167-1173.	0.8	185
196	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. <i>Haematologica</i> , 2011, 96, 62-68.	1.7	185
197	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. <i>Cancer</i> , 2007, 109, 1133-1137.	2.0	182
198	CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 48-58.	1.9	181

#	ARTICLE	IF	CITATIONS
199	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 4158-4164.	2.0	181
200	Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. <i>Blood</i> , 2015, 126, 2491-2501.	0.6	180
201	Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. <i>Blood</i> , 2017, 130, 1125-1131.	0.6	180
202	Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1108-1135.	2.3	179
203	Primary refractory and relapsed adult acute lymphoblastic leukemia. , 1999, 86, 1216-1230.		178
204	Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. <i>Blood</i> , 2009, 114, 261-263.	0.6	178
205	Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia. <i>Journal of Clinical Oncology</i> , 2010, 28, 437-444.	0.8	178
206	Homoharringtonine. <i>Cancer</i> , 2001, 92, 1591-1605.	2.0	177
207	Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. <i>Blood</i> , 2009, 113, 6330-6337.	0.6	175
208	High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. <i>Genome Research</i> , 2018, 28, 1345-1352.	2.4	175
209	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon- γ . <i>Blood</i> , 2003, 102, 83-86.	0.6	174
210	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. <i>Blood</i> , 2007, 109, 3214-3218.	0.6	174
211	Experience with gemtuzumab ozogamycin (œmylotarg) and all-trans retinoic acid in untreated acute promyelocytic leukemia. <i>Blood</i> , 2002, 99, 4222-4224.	0.6	173
212	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	0.8	173
213	Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1285-1292.	0.8	171
214	High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 676-683.	0.8	171
215	Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. <i>American Journal of Hematology</i> , 2014, 89, 547-556.	2.0	170
216	Use of arsenic trioxide (As ₂ O ₃) in the treatment of patients with acute promyelocytic leukemia. <i>Cancer</i> , 2003, 97, 2218-2224.	2.0	169

#	ARTICLE	IF	CITATIONS
217	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 1011-1019.	0.6	168
218	Chronic myelogenous leukemia in nonlymphoid blastic phase. , 1999, 86, 2632-2641.		167
219	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i> , 2014, 123, 2317-2324.	0.6	167
220	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2492-2499.	0.8	165
221	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. <i>Haematologica</i> , 2014, 99, 465-473.	1.7	165
222	The biology and therapy of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2003, 98, 1337-1354.	2.0	164
223	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1094-1105.	3.3	164
224	Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2575-2584.	3.3	164
225	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosomeâ€“positive chronic-phase chronic myeloid leukemia after failure of interferon-Î±. <i>Blood</i> , 2004, 104, 1979-1988.	0.6	163
226	Philadelphia Chromosomeâ€“Positive Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2007, 127, 642-650.	0.4	163
227	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. <i>Blood</i> , 2015, 126, 790-797.	0.6	162
228	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , 2021, 35, 440-453.	3.3	159
229	Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. <i>Blood</i> , 2009, 114, 2232-2235.	0.6	158
230	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2012, 30, 2204-2210.	0.8	158
231	Adult Acute Lymphoblastic Leukemia. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1645-1666.	1.4	158
232	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. <i>Lancet Haematology</i> , 2017, 4, e387-e398.	2.2	158
233	Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. <i>Blood</i> , 2009, 113, 6322-6329.	0.6	156
234	Hyperâ€“CVAD plus ponatinib versus hyperâ€“CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656.	2.0	156

#	ARTICLE	IF	CITATIONS
235	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	0.8	156
236	Rituximab in relapsed or refractory hairy cell leukemia. <i>Blood</i> , 2003, 102, 3906-3911.	0.6	155
237	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	1.7	154
238	Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. <i>Blood</i> , 2002, 100, 1590-1595.	0.6	153
239	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. <i>Blood</i> , 2009, 113, 6315-6321.	0.6	153
240	Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. <i>Clinical Therapeutics</i> , 2017, 39, 359-367.	1.1	152
241	Chronic myelogenous leukemia: A review. <i>American Journal of Medicine</i> , 1996, 100, 555-570.	0.6	151
242	Phase II Study of Dasatinib in Philadelphia Chromosome-Positive Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. <i>Clinical Cancer Research</i> , 2008, 14, 3906-3915.	3.2	151
243	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. <i>Blood</i> , 2009, 113, 2154-2160.	0.6	151
244	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. <i>Blood</i> , 2017, 130, 1514-1522.	0.6	151
245	Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. <i>Blood</i> , 2007, 109, 497-499.	0.6	150
246	Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. <i>Blood</i> , 2006, 108, 2811-2813.	0.6	149
247	Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-risk myelodysplastic syndrome and thrombocytopenia. <i>Cancer</i> , 2014, 120, 1838-1846.	2.0	149
248	Janus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia. <i>Cancer Research</i> , 2006, 66, 6468-6472.	0.4	148
249	Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1317-1326.	5.1	148
250	Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1993, 9, 343-350.	0.6	147
251	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. <i>Blood</i> , 2003, 101, 97-100.	0.6	147
252	Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related burkitt lymphoma/leukemia. <i>Cancer</i> , 2002, 94, 1492-1499.	2.0	146

#	ARTICLE	IF	CITATIONS
253	Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. <i>Blood</i> , 2006, 108, 45-51.	0.6	146
254	Comparison of idarubicin + ara-C, fludarabine + ara-C, and topotecan + ara-C based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. <i>Blood</i> , 2001, 98, 3575-3583.	0.6	145
255	Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. <i>Blood</i> , 2003, 101, 4714-4716.	0.6	145
256	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Blood</i> , 2016, 127, 2742-2750.	0.6	145
257	Dasatinib in imatinib-resistant or -intolerant chronic phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180034. <i>American Journal of Hematology</i> , 2016, 91, 869-874.	2.0	145
258	Monoclonal antibodies in acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 4010-4016.	0.6	144
259	Phase II, multicenter, randomized trial of CPX351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. <i>Cancer</i> , 2015, 121, 234-242.	2.0	144
260	Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. <i>Blood</i> , 2020, 136, 674-683.	0.6	144
261	Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. <i>Blood</i> , 2010, 116, 3163-3170.	0.6	143
262	Cause of death in patients with lower-risk myelodysplastic syndrome. <i>Cancer</i> , 2010, 116, 2174-2179.	2.0	142
263	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. <i>Blood Advances</i> , 2016, 1, 250-259.	2.5	142
264	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 496-508.	5.1	142
265	Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. <i>Blood</i> , 2002, 99, 4343-4349.	0.6	141
266	Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2004, 22, 1287-1292.	0.8	141
267	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. <i>Blood</i> , 2008, 111, 1774-1780.	0.6	140
268	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , 2016, 128, 902-910.	0.6	140
269	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. <i>Journal of Clinical Oncology</i> , 2011, 29, 1963-1970.	0.8	139
270	Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. <i>American Journal of Hematology</i> , 2016, 91, 252-265.	2.0	139

#	ARTICLE	IF	CITATIONS
271	Chromosomal abnormalities in Philadelphia chromosome- ϕ -negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2007, 110, 2991-2995.	0.6	138
272	Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. <i>Blood</i> , 2008, 112, 1366-1373.	0.6	138
273	The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. <i>Blood</i> , 2009, 114, 4361-4368.	0.6	138
274	Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival. <i>Leukemia and Lymphoma</i> , 2001, 42, 67-73.	0.6	137
275	Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine. <i>Journal of Clinical Oncology</i> , 1999, 17, 284-284.	0.8	135
276	Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. <i>Cancer</i> , 2007, 109, 899-906.	2.0	134
277	Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 36, 263-273.	0.6	133
278	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Blood</i> , 2011, 118, 4541-4546.	0.6	133
279	Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 1999, 17, 2819-2819.	0.8	132
280	Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2011, 29, 2240-2246.	0.8	131
281	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-174.	0.8	131
282	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <i>Leukemia and Lymphoma</i> , 2015, 56, 1643-1650.	0.6	130
283	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. <i>Science Translational Medicine</i> , 2016, 8, 355ra117.	5.8	130
284	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. <i>Blood</i> , 2003, 102, 4527-4534.	0.6	129
285	Outcome of adults with acute lymphocytic leukemia after second salvage therapy. <i>Cancer</i> , 2008, 113, 3186-3191.	2.0	129
286	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 1025-1036.	5.1	129
287	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 1894-1905.	2.5	129
288	Azacitidine. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 275-276.	21.5	128

#	ARTICLE	IF	CITATIONS
289	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	1.4	128
290	Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML. Blood, 2018, 132, 598-607.	0.6	128
291	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 2008, 112, 53-55.	0.6	127
292	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 897-901.	0.2	127
293	Acute lymphoblastic leukemia a comprehensive review with emphasis on biology and therapy. Cancer, 1995, 76, 2393-2417.	2.0	126
294	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer, 2003, 98, 1905-1911.	2.0	124
295	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood, 2013, 121, 4867-4874.	0.6	124
296	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood, 2014, 123, 1309-1318.	0.6	124
297	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 230.	3.4	124
298	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood, 2012, 120, 2573-2580.	0.6	123
299	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood, 2021, 137, 1792-1803.	0.6	123
300	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer, 2015, 121, 556-561.	2.0	122
301	Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer, 1994, 73, 2099-2106.	2.0	121
302	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 2007, 109, 248-255.	2.0	121
303	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer, 2007, 110, 1509-1519.	2.0	121
304	Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer, 1991, 68, 1536-1537.	2.0	120
305	Eradication of minimal residual disease in hairy cell leukemia. Blood, 2006, 107, 4658-4662.	0.6	120
306	Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer, 2007, 109, 713-717.	2.0	120

#	ARTICLE	IF	CITATIONS
307	Imatinib and beyondâ€”exploring the full potential of targeted therapy for CML. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 535-543.	12.5	120
308	Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 323-334.	0.2	120
309	Dasatinib. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 717-718.	21.5	119
310	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. <i>Blood</i> , 2009, 114, 2037-2043.	0.6	119
311	Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2011, 6, e23372.	1.1	119
312	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275.	0.6	119
313	Nilotinib-Associated Vascular Events. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 337-340.	0.2	118
314	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Reports</i> , 2015, 13, 2715-2727.	2.9	118
315	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 57-65.	0.8	118
316	Adult Acute Lymphoblastic Leukemia. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1517-1527.	1.4	117
317	Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Postâ€”Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 5587-5593.	0.8	117
318	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. <i>Cancer</i> , 2009, 115, 2482-2490.	2.0	116
319	Acute Lymphoblastic Leukemia, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1240-1279.	2.3	116
320	The BiTE (bispecific Tâ€œcell engager) platform: Development and future potential of a targeted immunoâ€œncology therapy across tumor types. <i>Cancer</i> , 2020, 126, 3192-3201.	2.0	116
321	Current and emerging treatment options in chronic myeloid leukemia. <i>Cancer</i> , 2007, 109, 2171-2181.	2.0	115
322	Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. <i>American Journal of Hematology</i> , 2012, 87, 1037-1045.	2.0	115
323	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. <i>Leukemia Research</i> , 2015, 39, 348-354.	0.4	115
324	High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses. <i>Journal of Clinical Oncology</i> , 2009, 27, 4754-4759.	0.8	114

#	ARTICLE	IF	CITATIONS
325	Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. <i>Cancer</i> , 2009, 115, 5382-5393.	2.0	114
326	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	2.0	114
327	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. <i>Cancer</i> , 2007, 109, 265-273.	2.0	113
328	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015, 125, 3236-3245.	0.6	113
329	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in <i>RAS</i> -mutant relapsed or refractory myeloid malignancies. <i>Cancer</i> , 2016, 122, 1871-1879.	2.0	113
330	Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients. <i>American Journal of Medicine</i> , 1994, 97, 60-65.	0.6	111
331	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2004, 100, 116-121.	2.0	111
332	Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>Cancer</i> , 2003, 97, 1711-1720.	2.0	110
333	Effects of <i>TET2</i> mutations on DNA methylation in chronic myelomonocytic leukemia. <i>Epigenetics</i> , 2012, 7, 201-207.	1.3	110
334	Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. <i>Cancer</i> , 2008, 113, 2097-2101.	2.0	109
335	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009, 115, 551-560.	2.0	108
336	Management of imatinib-resistant patients with chronic myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 103-117.	1.1	108
337	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. <i>Cancer</i> , 2003, 97, 2760-2766.	2.0	107
338	Staging of chronic myeloid leukemia in the imatinib era. <i>Cancer</i> , 2006, 106, 1306-1315.	2.0	107
339	Treatment with FLT3 inhibitor in patients with <i>FLT3</i> -mutated acute myeloid leukemia is associated with development of secondary <i>FLT3</i> "tyrosine kinase domain mutations. <i>Cancer</i> , 2014, 120, 2142-2149.	2.0	107
340	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. <i>Cancer</i> , 2008, 112, 837-845.	2.0	106
341	Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2008, 49, 690-695.	0.6	106
342	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	2.5	106

#	ARTICLE	IF	CITATIONS
343	Molecular characterization of <i>de novo</i> Philadelphia chromosome-positive acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 138-144.	0.6	105
344	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 20-34.	2.0	105
345	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 5681-5689.	2.5	105
346	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. <i>Cancer</i> , 2010, 116, 5568-5574.	2.0	104
347	Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. <i>Leukemia and Lymphoma</i> , 2013, 54, 1411-1417.	0.6	104
348	Adult Acute Myeloid Leukemia. <i>Mayo Clinic Proceedings</i> , 2006, 81, 247-260.	1.4	103
349	A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. <i>Blood</i> , 2007, 109, 4158-4163.	0.6	103
350	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	0.6	103
351	Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. <i>Blood</i> , 2011, 118, 3818-3823.	0.6	103
352	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. <i>Cancer</i> , 2017, 123, 2268-2273.	2.0	103
353	Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. <i>Blood Advances</i> , 2017, 1, 1167-1180.	2.5	103
354	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. <i>Blood</i> , 2005, 105, 2281-2286.	0.6	102
355	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. <i>Leukemia Research</i> , 2010, 34, 752-756.	0.4	102
356	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	2.0	102
357	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. <i>Lancet Haematology</i> , 2015, 2, e339-e346.	2.2	102
358	Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. <i>American Journal of Hematology</i> , 2016, 91, 819-823.	2.0	102
359	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 392-400.	1.2	102
360	Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. <i>American Journal of Medicine</i> , 1993, 94, 69-74.	0.6	101

#	ARTICLE	IF	CITATIONS
361	Decitabine and its role in the treatment of hematopoietic malignancies. <i>Leukemia and Lymphoma</i> , 2007, 48, 1472-1481.	0.6	101
362	TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. <i>Journal of Hematology and Oncology</i> , 2015, 8, 45.	6.9	101
363	Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. <i>Cancer</i> , 2006, 106, 1099-1109.	2.0	100
364	How I treat newly diagnosed chronic phase CML. <i>Blood</i> , 2012, 120, 1390-1397.	0.6	100
365	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. <i>Journal of Hematology and Oncology</i> , 2020, 13, 70.	6.9	100
366	High Cancer Drug Prices in the United States: Reasons and Proposed Solutions. <i>Journal of Oncology Practice</i> , 2014, 10, e208-e211.	2.5	99
367	Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?. <i>Mayo Clinic Proceedings</i> , 2015, 90, 500-504.	1.4	99
368	Acute myeloid leukemia—Major progress over four decades and glimpses into the future. <i>American Journal of Hematology</i> , 2016, 91, 131-145.	2.0	99
369	Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. <i>American Journal of Hematology</i> , 2019, 94, 257-265.	2.0	99
370	<i>t</i> (15;17) BCR Rearrangement—Negative Chronic Myelogenous Leukemia Revisited. <i>Journal of Clinical Oncology</i> , 2001, 19, 2915-2926.	0.8	98
371	Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 516-518.	0.6	98
372	Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 947-953.	2.0	98
373	Sequential Homoharringtonine and Interferon- α in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia. <i>Blood</i> , 1999, 93, 4149-4153.	0.6	97
374	The role of Src in solid and hematologic malignancies. <i>Cancer</i> , 2006, 107, 1918-1929.	2.0	97
375	An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. <i>Lancet Haematology</i> , 2019, 6, e194-e203.	2.2	97
376	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. <i>Clinical Cancer Research</i> , 2002, 8, 2177-87.	3.2	97
377	Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. <i>Blood</i> , 2007, 110, 3547-3551.	0.6	96
378	Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 530-533.	0.2	96

#	ARTICLE	IF	CITATIONS
379	Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2013, 31, 2548-2553.	0.8	96
380	Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases. <i>Cancer</i> , 2003, 97, 1920-1928.	2.0	95
381	Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009, 115, 3709-3718.	2.0	95
382	Gemtuzumab Ozogamicin: Time to Resurrect?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3921-3923.	0.8	95
383	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.	2.0	95
384	Troxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 762-771.	0.8	94
385	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. <i>Cancer</i> , 2009, 115, 5746-5751.	2.0	93
386	Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. <i>Blood</i> , 2010, 116, 5818-5823.	0.6	93
387	Outcome of patients with low-risk and intermediate-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium. <i>Cancer</i> , 2015, 121, 876-882.	2.0	93
388	Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. <i>Cancer</i> , 1986, 57, 2141-2145.	2.0	92
389	Important Therapeutic Targets in Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2007, 13, 1089-1097.	3.2	91
390	Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 2145-2155.	2.0	91
391	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2013, 121, 3703-3708.	0.6	91
392	Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. <i>Blood</i> , 2013, 122, 641-647.	0.6	91
393	Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). <i>Cancer</i> , 2014, 120, 3660-3668.	2.0	91
394	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	1.7	91
395	Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. <i>Journal of Clinical Oncology</i> , 2012, 30, 4323-4329.	0.8	90
396	Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. <i>Journal of Hematology and Oncology</i> , 2014, 7, 74.	6.9	90

#	ARTICLE	IF	CITATIONS
397	The emerging role of immune checkpoint based approaches in AML and MDS. <i>Leukemia and Lymphoma</i> , 2018, 59, 790-802.	0.6	90
398	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. <i>Lancet Oncology</i> , 2021, 22, 1597-1608.	5.1	90
399	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. <i>Cancer</i> , 2003, 98, 2636-2642.	2.0	89
400	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. <i>Cancer</i> , 2007, 109, 1556-1560.	2.0	89
401	Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. <i>Blood</i> , 2011, 118, 4353-4358.	0.6	89
402	High-dose chemotherapy in high-risk myelodysplastic syndrome. <i>Cancer</i> , 2001, 92, 1999-2015.	2.0	88
403	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. <i>British Journal of Haematology</i> , 2004, 125, 187-195.	1.2	88
404	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. <i>Blood</i> , 2011, 118, 4690-4693.	0.6	88
405	Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 515-529.	0.2	88
406	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 2611-2619.	2.0	88
407	Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1440-1454.	1.4	88
408	Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. <i>Cancer</i> , 2017, 123, 994-1002.	2.0	88
409	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	2.0	88
410	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. <i>Blood</i> , 2016, 127, 703-712.	0.6	87
411	Long-term follow-up of lower dose dasatinib (50mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 67-75.	2.0	87
412	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 723-733.	0.8	86
413	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	2.2	86
414	<i>DDX41</i> mutations in myeloid neoplasms are associated with male gender, <i>TP53</i> mutations and high-risk disease. <i>American Journal of Hematology</i> , 2019, 94, 757-766.	2.0	86

#	ARTICLE	IF	CITATIONS
415	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	2.5	86
416	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. <i>Oncotarget</i> , 2016, 7, 14172-14187.	0.8	86
417	Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Patients Treated with Fludarabine. <i>Leukemia and Lymphoma</i> , 1993, 11, 63-68.	0.6	85
418	Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 2003, 98, 1105-1113.	2.0	85
419	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , 2006, 108, 1421-1423.	0.6	85
420	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , 2006, 106, 120-127.	2.0	85
421	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	2.8	85
422	Chronic myelogenous leukemia: A review and update of therapeutic strategies. <i>Cancer</i> , 2003, 98, 437-457.	2.0	84
423	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. <i>Cancer</i> , 2008, 113, 1933-1952.	2.0	84
424	Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 524-531.	0.8	84
425	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933.	2.5	84
426	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	2.2	84
427	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. <i>Clinical Cancer Research</i> , 2002, 8, 2167-76.	3.2	84
428	Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options. <i>Current Oncology Reports</i> , 2012, 14, 387-394.	1.8	83
429	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2013, 161, 508-516.	1.2	83
430	Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 346-356.	1.1	83
431	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323.	2.5	83
432	The role of clofarabine in hematologic and solid malignancies—Development of a next-generation nucleoside analog. <i>Cancer</i> , 2005, 103, 1985-1995.	2.0	82

#	ARTICLE	IF	CITATIONS
433	Rituximab plus hyperâ€œCVAD</scp> alternating with <scp>MTX</scp>/Ara</scp> in patients with newly diagnosed mantle cell lymphoma: 15</year follow</sup> of a phase <scp>II</scp> study from the <scp>MD</scp> Anderson Cancer Center. British Journal of Haematology, 2016, 172, 80-88.	1.2	82
434	Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology, 2000, 18, 3513-3521.	0.8	81
435	Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer, 2007, 109, 1355-1359.	2.0	81
436	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematology,the, 2018, 5, e117-e126.	2.2	81
437	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e552-e561.	2.2	81
438	The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer, 1987, 59, 1739-1743.	2.0	80
439	Progress in the treatment of acute myeloid leukemia. Cancer, 2007, 110, 1900-1910.	2.0	80
440	Epigenetics of Acute Lymphocytic Leukemia. Seminars in Hematology, 2009, 46, 24-32.	1.8	80
441	<i>TET2</i> Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor</sup>Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Research, 2015, 75, 2833-2843.	0.4	80
442	Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica, 2021, 106, 894-898.	1.7	80
443	Acute promyelocytic leukemia current treatment algorithms. Blood Cancer Journal, 2021, 11, 123.	2.8	80
444	Outcomes of <i>TP53</i>-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer, 2021, 127, 3772-3781.	2.0	80
445	Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?. Blood, 1999, 93, 2755-2759.	0.6	79
446	Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood, 2005, 106, 4303-4307.	0.6	79
447	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome</sup>positive leukemias with the T315I mutation. Cancer, 2017, 123, 2875-2880.	2.0	79
448	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nature Communications, 2018, 9, 2670.	5.8	79
449	De novo acute myeloid leukemia: A population</sup>based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer, 2021, 127, 2049-2061.	2.0	79
450	Final results of a phase 2, open</sup>label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high</sup>risk myelodysplastic syndrome. Cancer, 2018, 124, 2758-2765.	2.0	78

#	ARTICLE	IF	CITATIONS
451	Central nervous system prophylaxis in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 2290-2300.	2.0	77
452	Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3876-3883.	0.8	77
453	Market spiral pricing of cancer drugs. <i>Cancer</i> , 2013, 119, 3900-3902.	2.0	77
454	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	0.8	77
455	Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2003, 9, 160-6.	3.2	77
456	Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia. <i>Blood</i> , 1998, 91, 3144-3147.	0.6	76
457	Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. <i>Cancer</i> , 2009, 115, 3217-3221.	2.0	76
458	Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 49-53.	1.2	76
459	Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 584-592.	2.0	76
460	Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. <i>American Journal of Hematology</i> , 2016, 91, 606-616.	2.0	76
461	Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. <i>British Journal of Haematology</i> , 2016, 174, 760-766.	1.2	76
462	Therapeutic implications of menin inhibition in acute leukemias. <i>Leukemia</i> , 2021, 35, 2482-2495.	3.3	76
463	Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. <i>Journal of Clinical Apheresis</i> , 1995, 10, 188-193.	0.7	75
464	Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2007, 26, 25-31.	0.8	75
465	Clofarabine: Past, present, and future. <i>Leukemia and Lymphoma</i> , 2007, 48, 1922-1930.	0.6	75
466	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , 2008, 112, 4839-4842.	0.6	75
467	The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. <i>Cancer</i> , 1986, 58, 924-927.	2.0	74
468	Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1991, 77, 291-295.	1.2	74

#	ARTICLE	IF	CITATIONS
469	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2012, 97, 1029-1035.	1.7	74
470	Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975-2008. <i>Cancer</i> , 2012, 118, 5811-5818.	2.0	74
471	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	2.0	74
472	Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. <i>Cancer</i> , 2021, 127, 1186-1207.	2.0	74
473	Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 656-664.	0.8	73
474	The rise and fall of gatekeeper mutations? The <i>BCR-ABL1</i> T315I paradigm. <i>Cancer</i> , 2012, 118, 293-299.	2.0	73
475	Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 734-737.	0.6	73
476	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. <i>Current Opinion in Hematology</i> , 2018, 25, 136-145.	1.2	73
477	Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. <i>Leukemia and Lymphoma</i> , 1996, 20, 435-439.	0.6	72
478	Practical advice for determining the role of <i>BCR-ABL</i> mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 1800-1811.	2.0	72
479	Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2015, 90, 755-768.	2.0	72
480	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018, 118, 1425-1433.	2.9	72
481	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing <i>BCR-ABL1</i> kinase domain mutations. <i>Blood</i> , 2011, 117, 3641-3647.	0.6	71
482	Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4260-4265.	0.8	71
483	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. <i>Lancet Haematology</i> , 2019, 6, e317-e327.	2.2	71
484	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 212-218.	0.2	71
485	AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. <i>Cancer</i> , 2005, 104, 1230-1236.	2.0	70
486	Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2010, 28, 285-291.	0.8	70

#	ARTICLE	IF	CITATIONS
487	Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 813-823.	0.8	70
488	Blinatumomab treatment of older adults with relapsed/refractory B ϵ precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. <i>Cancer</i> , 2016, 122, 2178-2185.	2.0	70
489	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B ϵ cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302.	2.0	70
490	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. <i>Cancer</i> , 2019, 125, 559-574.	2.0	70
491	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. <i>Lancet Haematology</i> , 2020, 7, e309-e319.	2.2	70
492	Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. <i>Clinical Cancer Research</i> , 2022, 28, 2753-2761.	3.2	70
493	Phase 1 study of polyethylene glycol formulation of interferon β -2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Blood</i> , 2001, 98, 1708-1713.	0.6	69
494	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. <i>Cancer</i> , 2003, 98, 888-893.	2.0	69
495	Expression of constitutively active Nuclear- κ B RelA transcription factor in blasts of acute myeloid leukemia. <i>Human Pathology</i> , 2004, 35, 246-253.	1.1	69
496	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.4	69
497	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 1413.	3.4	69
498	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 765-774.	2.0	69
499	Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. <i>Cancer</i> , 2008, 112, 1089-1095.	2.0	68
500	Treatment of core-binding factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. <i>Cancer</i> , 2008, 113, 3181-3185.	2.0	68
501	Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2008, 111, 2382-2384.	0.6	68
502	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	2.0	68
503	Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. <i>American Journal of Hematology</i> , 2022, 97, 1236-1256.	2.0	68
504	Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance. <i>Blood</i> , 1999, 93, 2075-2080.	0.6	67

#	ARTICLE	IF	CITATIONS
505	Pilot study of Imafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. <i>Cancer</i> , 2006, 106, 346-352.	2.0	67
506	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1091-1102.	2.3	67
507	Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. <i>Cancer</i> , 1986, 58, 2023-2030.	2.0	66
508	Neutrophilic-chronic myeloid leukemia. <i>Cancer</i> , 2002, 94, 2416-2425.	2.0	66
509	Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. <i>Cancer</i> , 2004, 101, 332-336.	2.0	66
510	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Cancer</i> , 2007, 110, 340-344.	2.0	66
511	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	2.2	66
512	Simultaneous homoharringtonine and interferon- α in the treatment of patients with chronic-phase chronic myelogenous leukemia. <i>Cancer</i> , 2002, 94, 2024-2032.	2.0	65
513	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. <i>Blood</i> , 2006, 107, 480-482.	0.6	65
514	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. <i>Blood</i> , 2011, 118, 1622-1631.	0.6	65
515	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	2.2	65
516	Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. <i>Blood</i> , 2017, 130, 2084-2091.	0.6	65
517	Recent advances in the treatment of acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2606-2621.	0.6	65
518	Role of maintenance chemotherapy in acute promyelocytic leukemia. <i>Cancer</i> , 1987, 59, 1258-1263.	2.0	64
519	Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients. <i>Leukemia and Lymphoma</i> , 2000, 39, 77-85.	0.6	64
520	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. <i>Blood</i> , 2011, 117, 1822-1827.	0.6	64
521	Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. <i>Cancer</i> , 2011, 117, 992-1000.	2.0	64
522	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. <i>British Journal of Haematology</i> , 2015, 168, 646-653.	1.2	64

#	ARTICLE	IF	CITATIONS
523	Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. <i>British Journal of Haematology</i> , 1994, 88, 94-100.	1.2	63
524	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—Comparison with historic experience. <i>Cancer</i> , 2005, 103, 2099-2108.	2.0	63
525	Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 687-691.	2.0	63
526	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 426-435.	2.0	63
527	Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 42.	6.9	63
528	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-CHCVAD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	2.0	63
529	CPX-351 (vyxeos) in AML. <i>Leukemia and Lymphoma</i> , 2020, 61, 288-297.	0.6	63
530	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	1.3	63
531	Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. <i>Cancer</i> , 2012, 118, 112-117.	2.0	62
532	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as frontline regimen in patients with core binding factor acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2014, 89, 964-968.	2.0	62
533	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	0.6	62
534	Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. <i>Blood</i> , 2002, 100, 1590-5.	0.6	62
535	Outcome of patients with acute myelogenous leukemia after second salvage therapy. <i>Cancer</i> , 2005, 104, 547-554.	2.0	61
536	Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. <i>Journal of Clinical Oncology</i> , 2009, 27, 3659-3663.	0.8	61
537	Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 54-59.	0.2	61
538	Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2013, 88, 1024-1029.	2.0	61
539	Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Cancer</i> , 2015, 121, 3894-3904.	2.0	61
540	Early results of lower dose dasatinib (50%mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 2740-2747.	2.0	61

#	ARTICLE	IF	CITATIONS
541	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. <i>Cancer</i> , 2019, 125, 4181-4192.	2.0	61
542	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 2607.	5.8	61
543	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.. <i>Blood</i> , 2004, 104, 23-23.	0.6	61
544	Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. <i>Blood</i> , 2011, 117, 5600-5606.	0.6	60
545	Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. <i>Cancer</i> , 2012, 118, 4471-4477.	2.0	60
546	Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2014, 55, 1925-1929.	0.6	60
547	A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 139-145.	0.2	60
548	Chronic myelogenous leukaemia with p185 BCR/ABL expression: characteristics and clinical significance. <i>British Journal of Haematology</i> , 1999, 107, 581-586.	1.2	59
549	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. <i>Cancer</i> , 2004, 100, 2592-2597.	2.0	59
550	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	2.0	59
551	Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 676-676.	0.6	59
552	CLINICAL COURSE AND THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA AND CHEMOTHERAPY. <i>Hematology/Oncology Clinics of North America</i> , 1998, 12, 31-80.	0.9	58
553	Decitabine in the treatment of myelodysplastic syndromes. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 9-22.	1.1	58
554	Failure of Hypomethylating Agent-Based Therapy in Myelodysplastic Syndromes. <i>Seminars in Oncology</i> , 2011, 38, 682-692.	0.8	58
555	Long-term outcomes in the second-line treatment of chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 897-906.	2.0	58
556	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. <i>Blood</i> , 2012, 119, 4524-4526.	0.6	58
557	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 1096-1104.	5.1	58
558	Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 282-287.	2.0	58

#	ARTICLE	IF	CITATIONS
559	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 47-53.	2.0	58
560	Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. <i>Leukemia</i> , 2020, 34, 799-810.	3.3	58
561	Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. <i>Cancer</i> , 1990, 65, 5-8.	2.0	57
562	Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2009, 115, 5490-5498.	2.0	57
563	NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1505-1512.	2.3	57
564	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 325-334.	2.0	57
565	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	0.7	57
566	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. <i>Blood</i> , 2015, 126, 323-323.	0.6	57
567	Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN- α Failure and in Late CML-CP, Comparison with Historical Controls. <i>Clinical Cancer Research</i> , 2004, 10, 68-75.	3.2	56
568	Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. <i>Cancer</i> , 2009, 115, 2912-2921.	2.0	56
569	A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 2704-2714.	3.2	56
570	Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 305-311.	1.7	56
571	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	2.5	56
572	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Oncotarget</i> , 2018, 9, 9714-9727.	0.8	56
573	THE HYPER-CVAD REGIMEN IN ADULT ACUTE LYMPHOCYTIC LEUKEMIA. <i>Hematology/Oncology Clinics of North America</i> , 2000, 14, 1381-1396.	0.9	55
574	Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2005, 80, 390-402.	1.4	55
575	Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 1674-1683.	3.2	55
576	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 319-326.	0.2	55

#	ARTICLE	IF	CITATIONS
577	Fludarabine therapy in hairy cell leukemia. <i>Cancer</i> , 1991, 67, 1291-1293.	2.0	54
578	Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long term follow-up results. <i>Cancer</i> , 1995, 75, 464-470.	2.0	54
579	ATM gene deletion in patients with adult acute lymphoblastic leukemia. , 2000, 88, 1057-1062.		54
580	Biphenotypic acute leukaemia: a case series. <i>British Journal of Haematology</i> , 2007, 138, 213-216.	1.2	54
581	Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 369-372.	0.8	54
582	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , 2014, 120, 373-380.	2.0	54
583	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285.	2.0	54
584	Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. <i>Cancer</i> , 2007, 110, 1295-1302.	2.0	53
585	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.	2.0	53
586	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573.	0.7	53
587	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2021, 7, 1213.	3.4	53
588	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. <i>Leukemia Research</i> , 2017, 59, 110-116.	0.4	53
589	In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. <i>Cancer</i> , 2002, 94, 2653-2662.	2.0	52
590	Clofarabine combinations as acute myeloid leukemia salvage therapy. <i>Cancer</i> , 2008, 113, 2090-2096.	2.0	52
591	Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2010, 28, 2755-2760.	0.8	52
592	A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. <i>Haematologica</i> , 2015, 100, 898-904.	1.7	52
593	Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. <i>Blood</i> , 2015, 126, 1699-1706.	0.6	52
594	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. <i>Blood</i> , 2017, 130, 1768-1771.	0.6	52

#	ARTICLE	IF	CITATIONS
595	Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. American Journal of Hematology, 2021, 96, 650-658.	2.0	52
596	Clinical and prognostic features of patients with philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer, 1987, 59, 297-300.	2.0	51
597	Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer, 1989, 63, 813-817.	2.0	51
598	β-Lactam regimens for the febrile neutropenic patient. Cancer, 1990, 65, 9-16.	2.0	51
599	Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia. Cancer, 1999, 85, 2583-2588.	2.0	51
600	Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer, 2007, 109, 907-914.	2.0	51
601	Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer, 2010, 116, 2673-2681.	2.0	51
602	Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 155-162.e1.	0.2	51
603	A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 401-410.	0.2	51
604	More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood, 2017, 129, 2584-2587.	0.6	51
605	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. American Journal of Hematology, 2020, 95, 612-622.	2.0	51
606	BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment. Journal of Clinical Investigation, 2019, 129, 1878-1894.	3.9	51
607	New Targeted Approaches in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2005, 23, 6316-6324.	0.8	50
608	Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Molecular Cancer Therapeutics, 2008, 7, 1130-1139.	1.9	50
609	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer, 2011, 117, 4869-4877.	2.0	50
610	Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 296-301.	0.2	50
611	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood, 2013, 122, 2807-2811.	0.6	50
612	Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clinical Pharmacology: Advances and Applications, 2013, 5, 85.	0.8	50

#	ARTICLE	IF	CITATIONS
613	Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2047-2060.	1.2	50
614	CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 749-755.	1.7	50
615	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with <i>NPM1</i> and <i>FLT3</i> internal tandem duplication genotypes. <i>Cancer</i> , 2019, 125, 1091-1100.	2.0	50
616	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	2.6	50
617	Advances in therapy for hairy cell leukemia. <i>Cancer</i> , 1993, 72, 5-16.	2.0	49
618	Treatment selection after imatinib resistance in chronic myeloid leukemia. <i>Targeted Oncology</i> , 2009, 4, 3-10.	1.7	49
619	Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 949-971.	0.9	49
620	Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 3173-3178.	0.8	49
621	Acute lymphoblastic leukemia in adolescents and young adults. <i>Cancer</i> , 2017, 123, 2398-2403.	2.0	49
622	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	2.0	49
623	Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1498-1504.	2.0	49
624	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive precursor acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 304-310.	2.0	49
625	Core binding factor acute myelogenous leukemia-2021 treatment algorithm. <i>Blood Cancer Journal</i> , 2021, 11, 114.	2.8	49
626	Sudden onset of the blastic phase of chronic myelogenous leukemia. <i>Cancer</i> , 2003, 98, 81-85.	2.0	48
627	Azacitidine. <i>Nature Reviews Drug Discovery</i> , 2005, 4, S6-S7.	21.5	48
628	Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. <i>Modern Pathology</i> , 2012, 25, 1405-1412.	2.9	48
629	The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1971-1984.	1.2	48
630	Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 584-591.	0.2	48

#	ARTICLE	IF	CITATIONS
631	Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 559-567.	0.2	48
632	Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient Care. <i>Journal of Clinical Oncology</i> , 2014, 32, 376-378.	0.8	48
633	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <i>Leukemia Research</i> , 2015, 39, 1367-1374.	0.4	48
634	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1755-1763.	2.9	48
635	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	2.8	48
636	Phase I study of liposomal daunorubicin in patients with acute leukemia. <i>Investigational New Drugs</i> , 1999, 17, 81-87.	1.2	47
637	Novel therapies for myelodysplastic syndromes. <i>Cancer</i> , 2004, 101, 226-241.	2.0	47
638	inv(16)(p13q22) in Chronic Myelogenous Leukemia in Blast Phase. <i>American Journal of Clinical Pathology</i> , 2005, 124, 807-814.	0.4	47
639	Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?. <i>Hematological Oncology</i> , 2006, 24, 181-188.	0.8	47
640	Evolution of Therapies for Chronic Myelogenous Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 465-476.	1.0	47
641	Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. <i>International Journal of Hematology</i> , 2014, 99, 616-624.	0.7	47
642	A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2015, 21, 985-994.	3.2	47
643	Toward Individualized Therapy in Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2015, 1, 820.	3.4	47
644	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. <i>Cancer</i> , 2017, 123, 3050-3060.	2.0	47
645	Advanced-phase chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2003, 40, 79-86.	1.8	46
646	Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. <i>Cancer</i> , 2008, 112, 1744-1753.	2.0	46
647	Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 981-995.	0.9	46
648	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. <i>Cancer</i> , 2011, 117, 572-580.	2.0	46

#	ARTICLE	IF	CITATIONS
649	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥60 years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 961-966.	2.0	46
650	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (<scp>AML</scp>) and myelodysplastic syndrome (<scp>MDS</scp>). <i>American Journal of Hematology</i> , 2016, 91, 227-232.	2.0	46
651	<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. <i>Blood</i> , 2022, 140, 58-72.	0.6	46
652	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 1991, 68, 1201-1207.	2.0	45
653	Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. <i>Cancer</i> , 1995, 76, 1564-1570.	2.0	45
654	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. <i>Leukemia and Lymphoma</i> , 2007, 48, 283-289.	0.6	45
655	In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. <i>Nature Medicine</i> , 2007, 13, 14-14.	15.2	45
656	First-line therapy for chronic myeloid leukemia: Past, present, and future. <i>American Journal of Hematology</i> , 2009, 84, 287-293.	2.0	45
657	Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. <i>Cancer</i> , 2010, 116, 2665-2672.	2.0	45
658	Molecular monitoring in chronic myeloid leukemia. <i>Cancer</i> , 2008, 112, 2112-2118.	2.0	44
659	Tyrosine kinase inhibitors in acute and chronic leukemias. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 927-938.	0.9	44
660	Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. <i>Cancer</i> , 2015, 121, 1637-1644.	2.0	44
661	Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up. <i>Leukemia Research</i> , 2015, 39, 520-524.	0.4	44
662	Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 2151-2160.	2.0	44
663	A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML). <i>Blood</i> , 2014, 124, 118-118.	0.6	44
664	Significance and correlations of molecular analysis results in patients with philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. <i>American Journal of Medicine</i> , 1988, 85, 639-644.	0.6	43
665	Philadelphia Chromosome-Negative Chronic Myelogenous Leukemia and Chronic Myelomonocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 1990, 4, 389-404.	0.9	43
666	Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. <i>Cancer</i> , 1993, 72, 2155-2160.	2.0	43

#	ARTICLE	IF	CITATIONS
667	All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. <i>Cancer</i> , 1994, 73, 2946-2952.	2.0	43
668	Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. <i>Investigational New Drugs</i> , 2012, 30, 1107-1115.	1.2	43
669	Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2013, 88, 831-837.	2.0	43
670	The role of clofarabine in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 688-698.	0.6	43
671	Are high drug prices for hematologic malignancies justified? A critical analysis. <i>Cancer</i> , 2015, 121, 3372-3379.	2.0	43
672	TET3 overexpression is an independent adverse prognostic factor in <i>de novo</i> myelodysplastic syndromes with fibrosis. <i>British Journal of Haematology</i> , 2015, 171, 91-99.	1.2	43
673	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. <i>Cancer</i> , 2018, 124, 1722-1732.	2.0	43
674	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. <i>Blood</i> , 2019, 133, 2348-2351.	0.6	43
675	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	2.2	43
676	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. <i>Blood</i> , 2014, 124, 3135-3135.	0.6	43
677	Impact of FLT3-LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 2744-2752.	3.2	43
678	Intensive treatment of acute leukemia in adults 70 years of age and older. <i>Cancer</i> , 1987, 60, 149-155.	2.0	42
679	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. <i>Haematologica</i> , 2014, 99, 1204-1211.	1.7	42
680	Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. <i>Blood</i> , 2016, 127, 1398-1402.	0.6	42
681	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 684-695.e6.	0.2	42
682	Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. <i>American Journal of Hematology</i> , 2021, 96, 589-598.	2.0	42
683	Targeting the Kinase Activity of the BCR-ABL Fusion Protein in Patients with Chronic Myeloid Leukemia. <i>Current Molecular Medicine</i> , 2005, 5, 615-623.	0.6	41
684	The Biology of Chronic Myelogenous Leukemia: Implications for Imatinib Therapy. <i>Seminars in Hematology</i> , 2007, 44, 4-14.	1.8	41

#	ARTICLE	IF	CITATIONS
685	Diagnosis and management of chronic myeloid leukemia. <i>Cancer</i> , 2007, 109, 1365-1375.	2.0	41
686	Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?. <i>Haematologica</i> , 2012, 97, 919-925.	1.7	41
687	Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. <i>British Journal of Haematology</i> , 2016, 172, 97-110.	1.2	41
688	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. <i>British Journal of Haematology</i> , 2017, 178, 906-913.	1.2	41
689	Poor outcomes associated with +der(22)t(9;22) and $\hat{a}^9/9p$ in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	2.0	41
690	Advanced-phase chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2003, 40, 79-86.	1.8	41
691	AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.. <i>Blood</i> , 2009, 114, 636-636.	0.6	41
692	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacididine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	0.8	41
693	Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. <i>American Journal of Medicine</i> , 1996, 100, 452-455.	0.6	40
694	Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, 6, 142-160.	0.1	40
695	Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1263-1265.	1.7	40
696	The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities. <i>Cancer</i> , 2009, 115, 5202-5209.	2.0	40
697	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2010, 116, 1419-1430.	2.0	40
698	Myelopathy following intrathecal chemotherapy in adults: a single institution experience. <i>Journal of Neuro-Oncology</i> , 2015, 122, 391-398.	1.4	40
699	Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2375-2382.	2.0	40
700	Progress in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 139-151.	0.2	40
701	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018, 131, 1820-1832.	0.6	40
702	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2018, 93, 84-90.	2.0	40

#	ARTICLE	IF	CITATIONS
703	Mutational landscape of myelodysplastic/myeloproliferative neoplasmâ€“unclassifiable. <i>Blood</i> , 2018, 132, 2100-2103.	0.6	40
704	Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2214-2222.	0.6	40
705	Impact of TKIs postâ€“allogeneic hematopoietic cell transplantation in Philadelphia chromosomeâ€“positive ALL. <i>Blood</i> , 2020, 136, 1786-1789.	0.6	40
706	Outcomes in patients with newly diagnosed <i>TP53</i> -mutated acute myeloid leukemia with or without venetoclaxâ€“based therapy. <i>Cancer</i> , 2021, 127, 3541-3551.	2.0	40
707	Clinical Profile of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2019, 134, 734-734.	0.6	40
708	HyperCVAD for VAD-resistant multiple myeloma. , 1996, 52, 77-81.		39
709	New agents in acute myeloid leukemia and other myeloid disorders. <i>Cancer</i> , 2004, 100, 441-454.	2.0	39
710	Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. <i>Cancer</i> , 2004, 100, 1459-1471.	2.0	39
711	Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. <i>Cancer</i> , 2009, 115, 3935-3943.	2.0	39
712	Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?. <i>Mayo Clinic Proceedings</i> , 2009, 84, 161-169.	1.4	39
713	Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1451-1462.	0.6	39
714	Improving the detection of patients with inherited predispositions to hematologic malignancies using nextâ€“generation sequencingâ€“based leukemia prognostication panels. <i>Cancer</i> , 2018, 124, 2704-2713.	2.0	39
715	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 257-265.	0.2	39
716	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 639387.	1.3	39
717	Pneumonia with <i>Cunninghamella</i> species in patients with hematologic malignancies: A case report and review of the literature. <i>Cancer</i> , 1986, 58, 1534-1536.	2.0	38
718	Leukemia Cutis in Acute Promyelocytic Leukemia: Report of Three Cases After Treatment with All-Trans Retinoic Acid. <i>Leukemia and Lymphoma</i> , 1994, 14, 453-456.	0.6	38
719	Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. <i>Journal of Clinical Oncology</i> , 2003, 21, 1050-1056.	0.8	38
720	Decitabine Dosing Schedules. <i>Seminars in Hematology</i> , 2005, 42, S17-S22.	1.8	38

#	ARTICLE	IF	CITATIONS
721	Predicting survival of patients with hypocellular myelodysplastic syndrome. <i>Cancer</i> , 2012, 118, 4462-4470.	2.0	38
722	Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. <i>American Journal of Hematology</i> , 2015, 90, 27-30.	2.0	38
723	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 599-606.	2.0	38
724	Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. <i>American Journal of Hematology</i> , 2018, 93, 286-295.	2.0	38
725	Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. <i>Lancet Haematology</i> , 2019, 6, e398-e408.	2.2	38
726	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3 internal tandem duplication mutation positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	2.0	38
727	Disseminated Intravascular Coagulation in Adult Acute Lymphoblastic Leukemia: Frequent Complications with Fibrinogen Levels Less than 100 mg/dl. <i>Leukemia and Lymphoma</i> , 1996, 21, 85-92.	0.6	37
728	HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. <i>Modern Pathology</i> , 2007, 20, 54-62.	2.9	37
729	Targeted therapy in chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 99-110.	1.1	37
730	Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 150, 303-312.	1.2	37
731	Chemotherapy Drug Shortages in the United States: Genesis and Potential Solutions. <i>Journal of Clinical Oncology</i> , 2012, 30, 692-694.	0.8	37
732	A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 223-230.	0.2	37
733	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	2.0	37
734	Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. <i>Blood Advances</i> , 2017, 1, 2541-2552.	2.5	37
735	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1618.	1.8	37
736	Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	2.5	37
737	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	3.3	37
738	Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 449-457.	2.5	37

#	ARTICLE	IF	CITATIONS
739	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. <i>Blood</i> , 2019, 134, 643-643.	0.6	37
740	A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naïve Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy. <i>Blood</i> , 2015, 126, 327-327.	0.6	37
741	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. <i>Blood Advances</i> , 2022, 6, 4006-4014.	2.5	37
742	Contribution of β -2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). <i>Blood</i> , 2003, 102, 1622-1625.	0.6	36
743	A phase I study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2011, 117, 1236-1244.	2.0	36
744	Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2012, 157, 312-320.	1.2	36
745	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. <i>British Journal of Haematology</i> , 2015, 171, 471-477.	1.2	36
746	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncology</i> , 2016, 12, 293-302.	1.1	36
747	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. <i>Haematologica</i> , 2016, 101, e224-e227.	1.7	36
748	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 845-850.	2.0	36
749	Toward the potential cure of leukemias in the next decade. <i>Cancer</i> , 2018, 124, 4301-4313.	2.0	36
750	Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. <i>Blood</i> , 2015, 126, 1306-1306.	0.6	36
751	Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes. <i>Cancer</i> , 1995, 76, 985-991.	2.0	35
752	Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2004, 100, 2396-2402.	2.0	35
753	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. <i>Leukemia and Lymphoma</i> , 2014, 55, 2879-2886.	0.6	35
754	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015, 90, 193-196.	2.0	35
755	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	2.5	35
756	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. <i>Blood</i> , 2017, 130, 723-723.	0.6	35

#	ARTICLE	IF	CITATIONS
757	Accelerated and blastic phases of chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 753-774.	0.9	34
758	Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 7817-7824.	3.2	34
759	Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast-Phase Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 244-251.	0.2	34
760	Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis. <i>Current Treatment Options in Oncology</i> , 2013, 14, 127-143.	1.3	34
761	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <i>Blood Advances</i> , 2018, 2, 1807-1816.	2.5	34
762	Prognosis of patients with intermediate risk IPSS myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS. <i>American Journal of Hematology</i> , 2018, 93, 1245-1253.	2.0	34
763	Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. <i>Blood Cancer Journal</i> , 2020, 10, 81.	2.8	34
764	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021, 106, 2121-2130.	1.7	34
765	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2489-2499.	2.0	34
766	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 283-283.	0.6	34
767	Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN- γ -2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 6247-6255.	3.2	33
768	Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 679-687.	1.9	33
769	Clofarabine in leukemia. <i>Expert Review of Hematology</i> , 2010, 3, 15-22.	1.0	33
770	Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics. <i>BMC Cancer</i> , 2014, 14, 69.	1.1	33
771	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. <i>Blood Reviews</i> , 2014, 28, 179-187.	2.8	33
772	The absolute percent deviation of IGHV mutation rather than a 98% cutoff predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. <i>British Journal of Haematology</i> , 2018, 180, 33-40.	1.2	33
773	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 2193-2205.	2.0	33
774	Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. <i>Frontiers in Oncology</i> , 2020, 10, 582213.	1.3	33

#	ARTICLE	IF	CITATIONS
775	Prognostic factors for progression in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	2.0	33
776	First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2004, 104, 67-67.	0.6	33
777	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. <i>Journal of Hematology and Oncology</i> , 2022, 15, 1.	6.9	33
778	<scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	2.0	33
779	Hypomethylating agent and venetoclax with FLT3 inhibitor â€tripleâ€therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	2.8	33
780	Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of philadelphia chromosome-negative cells in chronic myelogenous leukemia. <i>Cancer</i> , 1991, 67, 2959-2965.	2.0	32
781	Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. <i>Leukemia Research</i> , 2004, 28, 991-994.	0.4	32
782	Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. <i>BMC Structural Biology</i> , 2009, 9, 58.	2.3	32
783	Questions regarding frontline therapy of acute myeloid leukemia. <i>Cancer</i> , 2010, 116, 4896-4901.	2.0	32
784	Outcome of therapyâ€related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. <i>Cancer</i> , 2011, 117, 110-115.	2.0	32
785	Very longâ€term followâ€up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. <i>Cancer</i> , 2012, 118, 3116-3122.	2.0	32
786	Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. <i>Leukemia Research</i> , 2013, 37, 1461-1467.	0.4	32
787	Outcomes of adults with relapsed or refractory Burkitt and highâ€grade Bâ€cell leukemia/lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E114-E117.	2.0	32
788	<scp>S</scp>ignificance of recurrence of minimal residual disease detected by multiâ€parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. <i>American Journal of Hematology</i> , 2017, 92, 279-285.	2.0	32
789	Prognostic significance of baseline <i>FLT3</i>â€TD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	2.0	32
790	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.4	32
791	Phase II study of azacitidine with pembrolizumab in patients with intermediateâ€1 or higherâ€risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2021, 195, 378-387.	1.2	32
792	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	2.8	32

#	ARTICLE	IF	CITATIONS
793	Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?. <i>Blood</i> , 1999, 93, 2755-2759.	0.6	32
794	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. <i>Investigational New Drugs</i> , 1999, 17, 89-95.	1.2	31
795	Antiangiogenic Therapy in Leukemia. <i>Acta Haematologica</i> , 2001, 106, 190-207.	0.7	31
796	Advances in the Therapy of Chronic Idiopathic Myelofibrosis. <i>Oncologist</i> , 2006, 11, 929-943.	1.9	31
797	Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2509-2516.	1.9	31
798	Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the "Best" Therapy?. <i>Current Oncology Reports</i> , 2010, 12, 302-313.	1.8	31
799	Monitoring molecular response in chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 1113-1122.	2.0	31
800	Considerations in the Management of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 1512-1516.	0.8	31
801	Adherence to BCR-ABL Inhibitors: Issues for CML Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 223-229.	0.2	31
802	Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 73-95.	0.8	31
803	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. <i>Cancer</i> , 2017, 123, 629-637.	2.0	31
804	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377.	0.6	31
805	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. <i>Oncotarget</i> , 2016, 7, 55083-55097.	0.8	31
806	Chronic myelogenous leukemia: update on biology and treatment. <i>Oncology</i> , 1999, 13, 169-80; discussion 181, 184.	0.4	31
807	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	2.0	31
808	The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 993-997.	0.6	30
809	Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Cancer</i> , 2006, 107, 1525-1529.	2.0	30
810	The role of decitabine in the treatment of myelodysplastic syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 65-73.	0.9	30

#	ARTICLE	IF	CITATIONS
811	Clofarabine for the treatment of acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 113-118.	1.1	30
812	A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. <i>Cancer</i> , 2007, 110, 955-964.	2.0	30
813	Thrombocytopenia in Patients With Myelodysplastic Syndromes. <i>Seminars in Hematology</i> , 2010, 47, 274-280.	1.8	30
814	Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 361-366.	0.2	30
815	Prediction model for mortality after intracranial hemorrhage in patients with leukemia. <i>American Journal of Hematology</i> , 2011, 86, 546-549.	2.0	30
816	Ruxolitinib for Myelofibrosis—An Update of Its Clinical Effects. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 638-645.	0.2	30
817	Prognostic impact of <i>RAS</i> mutations in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 365-369.	2.0	30
818	<i>BRAF</i> kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type <i>RAS</i> . <i>American Journal of Hematology</i> , 2014, 89, 499-504.	2.0	30
819	Impact of comorbidities by ACE27 in the revised IPSS for patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2014, 89, 509-516.	2.0	30
820	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. <i>Cancer</i> , 2016, 122, 238-248.	2.0	30
821	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. <i>American Journal of Hematology</i> , 2017, 92, 155-160.	2.0	30
822	A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 658-663.e2.	0.2	30
823	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.	2.0	30
824	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3867-3867.	0.6	30
825	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). <i>Blood</i> , 2014, 124, 519-519.	0.6	30
826	Terminal Deoxynucleotidyl Transferase–Negative Acute Lymphoblastic Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 92-97.	1.2	30
827	Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. <i>JAMA Oncology</i> , 2022, 8, 1340.	3.4	30
828	Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. <i>Cancer</i> , 1987, 60, 1708-1712.	2.0	29

#	ARTICLE	IF	CITATIONS
829	Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. <i>Cancer</i> , 1989, 64, 16-22.	2.0	29
830	Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. <i>Core Evidence</i> , 2010, 4, 207.	4.7	29
831	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. <i>Cancer</i> , 2010, 116, 3631-3637.	2.0	29
832	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. <i>Haematologica</i> , 2013, 98, 1686-1688.	1.7	29
833	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline <i>DDX41</i> mutation. <i>American Journal of Hematology</i> , 2020, 95, 227-229.	2.0	29
834	Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. <i>Cancer</i> , 2020, 126, 1152-1160.	2.0	29
835	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126.	2.5	29
836	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. <i>Leukemia</i> , 2021, 35, 3044-3058.	3.3	29
837	Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML). <i>Journal of Clinical Oncology</i> , 2020, 38, 7501-7501.	0.8	29
838	The breakpoint cluster region site in patients with Philadelphia chromosome-“positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. <i>Cancer</i> , 1995, 76, 992-997.	2.0	28
839	Practical Guidelines for the Management of Chronic Myelogenous Leukemia with Interferon Alpha. <i>Leukemia and Lymphoma</i> , 1996, 23, 247-252.	0.6	28
840	DNA methylation in haematological malignancies: the role of decitabine. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1985-1993.	1.9	28
841	New Targeted Therapies for Chronic Myelogenous Leukemia: Opportunities to Overcome Imatinib Resistance. <i>Seminars in Hematology</i> , 2007, 44, 25-31.	1.8	28
842	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. <i>Modern Pathology</i> , 2015, 28, 373-382.	2.9	28
843	Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera “single center experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 237-239.	0.6	28
844	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295.	2.0	28
845	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with <i>NPM1</i> mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	1.2	28
846	The clinical development of antibody-“drug conjugates “ lessons from leukaemia. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 418-433.	12.5	28

#	ARTICLE	IF	CITATIONS
847	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 580-597.	0.2	28
848	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with <i>IDH 1/2</i> Mutations. <i>Blood</i> , 2020, 136, 5-7.	0.6	28
849	Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. <i>Cancer</i> , 1993, 72, 2950-2955.	2.0	27
850	Adult acute lymphocytic leukemia: Critical review of current knowledge. <i>American Journal of Medicine</i> , 1994, 97, 176-184.	0.6	27
851	Emerging Safety Issues with Imatinib and Other Abl Tyrosine Kinase Inhibitors. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S105-S112.	1.4	27
852	Practical Management of Toxicities Associated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, S82-S88.	1.4	27
853	Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. <i>Leukemia and Lymphoma</i> , 2008, 49, 1399-1402.	0.6	27
854	Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. <i>Blood</i> , 2010, 116, 1737-1746.	0.6	27
855	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 943-954.	1.9	27
856	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <i>American Journal of Hematology</i> , 2015, 90, 769-773.	2.0	27
857	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. <i>Leukemia Research</i> , 2016, 41, 43-47.	0.4	27
858	Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 193-200.	0.7	27
859	Cancer Drugs: An International Comparison of Postlicensing Price Inflation. <i>Journal of Oncology Practice</i> , 2017, 13, e538-e542.	2.5	27
860	Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2018, 97, 109-121.	0.8	27
861	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2018, 7, 5457-5469.	1.3	27
862	New drug approvals in oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 140-146.	12.5	27
863	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <i>Lancet Haematology</i> , 2021, 8, e922-e933.	2.2	27
864	The Expanding Role of Fludarabine in Hematologic Malignancies. <i>Leukemia and Lymphoma</i> , 1994, 14, 11-16.	0.6	26

#	ARTICLE	IF	CITATIONS
865	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 2003, 97, 2225-2228.	2.0	26
866	Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. <i>Current Opinion in Oncology</i> , 2006, 18, 578-583.	1.1	26
867	Relapse and death during first remission in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 633-634.	1.7	26
868	Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. <i>Cancer</i> , 2009, 115, 2147-2154.	2.0	26
869	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. <i>Cancer</i> , 2012, 118, 722-728.	2.0	26
870	Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 435-440.	0.2	26
871	The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. <i>Clinical Cancer Research</i> , 2015, 21, 4561-4568.	3.2	26
872	A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 660-667.	2.0	26
873	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395.	2.0	26
874	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	2.2	26
875	Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. <i>Cancer</i> , 1992, 69, 410-412.	2.0	25
876	Detection of High-Frequency and Novel DNMT3A Mutations in Acute Myeloid Leukemia by High-Resolution Melting Curve Analysis. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 336-345.	1.2	25
877	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 345-350.	1.1	25
878	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 152-162.	0.2	25
879	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 369.	1.3	25
880	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	0.7	25
881	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	2.0	25
882	Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. <i>Haematologica</i> , 2020, 105, 1567-1574.	1.7	25

#	ARTICLE	IF	CITATIONS
883	Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2000, 96, 768-770.	0.6	25
884	Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7042-7042.	0.8	25
885	TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10782.	1.8	25
886	Prediction of early (4â€week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78.	2.0	25
887	The management of locally advanced breast cancer: a combined modality approach. <i>European Journal of Cancer & Clinical Oncology</i> , 1984, 20, 1353-1361.	0.9	24
888	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. <i>Cancer</i> , 2005, 104, 777-780.	2.0	24
889	Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. <i>British Journal of Haematology</i> , 2006, 134, 58-60.	1.2	24
890	A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. <i>Leukemia Research</i> , 2006, 30, 1591-1595.	0.4	24
891	BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors. <i>Acta Haematologica</i> , 2009, 121, 27-31.	0.7	24
892	Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. <i>Blood</i> , 2009, 113, 5058-5063.	0.6	24
893	Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 477-484.	0.2	24
894	Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. <i>American Journal of Hematology</i> , 2015, 90, E139-41.	2.0	24
895	Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all- <i>trans</i> -retinoic acid plus chemotherapy or with all- <i>trans</i> -retinoic acid plus arsenic trioxide. <i>Leukemia and Lymphoma</i> , 2015, 56, 1342-1345.	0.6	24
896	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2017, 92, 674-682.	2.0	24
897	First Report of Clinical Response to Venetoclax in Early T-Cell Precursor Acute Lymphoblastic Leukemia. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	24
898	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. <i>Cancer Medicine</i> , 2019, 8, 6559-6565.	1.3	24
899	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1670-1677.	2.5	24
900	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-â€hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-â€negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	2.0	24

#	ARTICLE	IF	CITATIONS
901	Tenâ€day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity scoreâ€matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220.	2.0	24
902	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419.	2.5	24
903	ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). <i>Blood</i> , 2010, 116, 207-207.	0.6	24
904	Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7011-7011.	0.8	24
905	Complete hematologic and cytogenetic response to 2-amino-9-?-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase. <i>Cancer</i> , 1999, 85, 58-64.	2.0	23
906	Sti-571 in Chronic Myelogenous Leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 15-24.	1.2	23
907	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. <i>Leukemia Research</i> , 2003, 27, 1091-1096.	0.4	23
908	Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 205-210.	0.2	23
909	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1599-1607.	1.1	23
910	High cancer drug prices 4 years laterâ€Progress and prospects. <i>Cancer</i> , 2017, 123, 1292-1297.	2.0	23
911	Myeloid neoplasms with concurrent <i>BCRâ€ABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm. <i>American Journal of Hematology</i> , 2017, 92, 520-528.	2.0	23
912	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. <i>Cancer</i> , 2018, 124, 2534-2540.	2.0	23
913	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. <i>Modern Pathology</i> , 2018, 31, 1141-1154.	2.9	23
914	Prediction for sustained deep molecular response of <i>BCRâ€ABL1</i> levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	2.0	23
915	The importance of greater speed in drug development for advanced malignancies. <i>Cancer Medicine</i> , 2018, 7, 1824-1836.	1.3	23
916	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007.	2.0	23
917	An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 208-208.	0.6	23
918	Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-?. <i>Cancer</i> , 2000, 89, 1482-1489.	2.0	22

#	ARTICLE	IF	CITATIONS
919	Therapeutic choices in younger patients with chronic myelogenous leukemia. <i>Cancer</i> , 2000, 89, 1647-1658.	2.0	22
920	New Strategies in Chronic Myeloid Leukemia. <i>International Journal of Hematology</i> , 2006, 83, 289-293.	0.7	22
921	Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome. <i>Clinical Cancer Research</i> , 2008, 14, 509-514.	3.2	22
922	Significance of Thrombocytopenia in Myelodysplastic Syndromes: Associations and Prognostic Implications. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 237-241.	0.2	22
923	Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 58-66.	1.2	22
924	Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 187-194.	1.2	22
925	Usefulness of CD11a and CD18 in Flow Cytometric Immunophenotypic Analysis for Diagnosis of Acute Promyelocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2012, 138, 744-750.	0.4	22
926	Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2013, 50, 271-283.	1.8	22
927	Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1433-1452.	1.1	22
928	The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2013, 3, 218.	1.3	22
929	Comprehensive Craniospinal Radiation for Controlling Central Nervous System Leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1119-1125.	0.4	22
930	The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. <i>Cancer</i> , 2016, 122, 1160-1168.	2.0	22
931	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 519-528.	1.7	22
932	Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. <i>Blood Cancer Journal</i> , 2018, 8, 88.	2.8	22
933	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. <i>Leukemia</i> , 2020, 34, 872-881.	3.3	22
934	Phase 1 study of combinatorial sorafenib, <sc>G-CSF</sc>, and plerixafor treatment in relapsed/refractory, <sc>FLT3-ITD</sc>-mutated acute myelogenous leukemia patients. <i>American Journal of Hematology</i> , 2020, 95, 1296-1303.	2.0	22
935	Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. <i>Blood Cancer Journal</i> , 2021, 11, 60.	2.8	22
936	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	3.3	22

#	ARTICLE	IF	CITATIONS
937	Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. <i>Blood</i> , 2019, 134, 2924-2924.	0.6	22
938	Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition. <i>Blood</i> , 2013, 122, 866-866.	0.6	22
939	Interleukin 11 May improve thrombocytopenia associated with Imatinib mesylate therapy in chronic Myelogenous leukemia. <i>Leukemia Research</i> , 2004, 28, 613-618.	0.4	21
940	Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. <i>Leukemia Research</i> , 2008, 32, 643-649.	0.4	21
941	Acute Lymphoblastic Leukemia With Burkitt-like Morphologic Features and High Myeloperoxidase Activity. <i>American Journal of Clinical Pathology</i> , 2009, 132, 182-185.	0.4	21
942	Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Cancer</i> , 2010, 116, 93-97.	2.0	21
943	Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. <i>Cancer</i> , 2010, 116, 3152-3159.	2.0	21
944	Pharmacokinetic evaluation of decitabine for the treatment of leukemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 661-672.	1.5	21
945	Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 327-335.	2.0	21
946	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 365-373.	1.1	21
947	Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. <i>Leukemia Research</i> , 2015, 39, 822-827.	0.4	21
948	Phase II study of methotrexate, vincristine, pegylated asparaginase, and dexamethasone (<sc>MO</sc>p<sc>AD</sc>) in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 120-124.	2.0	21
949	Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 2100-2101.	13.9	21
950	Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. <i>Clinical Epigenetics</i> , 2019, 11, 106.	1.8	21
951	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent <sc>CD</sc>33 expression and <i>in vitro</i> response to targeted <sc>CD</sc>33 therapy. <i>British Journal of Haematology</i> , 2019, 186, 538-548.	1.2	21
952	Recent Advances in Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 106-118.	1.2	21
953	Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1855-1866.	2.0	21
954	Long-term results of frontline dasatinib in chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 1502-1511.	2.0	21

#	ARTICLE	IF	CITATIONS
955	Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. <i>Cancer</i> , 2021, 127, 554-559.	2.0	21
956	Novel Therapies in Acute Lymphoblastic Leukemia. , 2008, , 237-246.		21
957	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. <i>Cancer</i> , 2001, 92, 2501-2507.	2.0	20
958	Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. <i>Cancer</i> , 2002, 94, 2996-2999.	2.0	20
959	New approaches in the treatment of myelofibrosis. <i>Cancer</i> , 2005, 103, 32-43.	2.0	20
960	Advances in the biology and therapy of patients with chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 395-407.	0.7	20
961	Third-Generation Tyrosine Kinase Inhibitors and Beyond. <i>Seminars in Hematology</i> , 2010, 47, 371-380.	1.8	20
962	Sapacitabine for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 541-555.	1.9	20
963	Suboptimal responses in chronic myeloid leukemia. <i>Cancer</i> , 2012, 118, 1181-1191.	2.0	20
964	The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 302-306.	0.2	20
965	Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. <i>British Journal of Haematology</i> , 2013, 161, 659-666.	1.2	20
966	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2238-2241.	0.6	20
967	The opioid epidemic in the United States—Overview, origins, and potential solutions. <i>Cancer</i> , 2018, 124, 4279-4286.	2.0	20
968	Response kinetics and factors predicting survival in core-binding factor leukemia. <i>Leukemia</i> , 2018, 32, 2698-2701.	3.3	20
969	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	2.0	20
970	Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 207-223.	1.2	20
971	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. <i>Blood Cancer Journal</i> , 2020, 10, 61.	2.8	20
972	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon- γ regimens for early chronic phase. <i>Cancer</i> , 2003, 98, 1430-1437.	2.0	19

#	ARTICLE	IF	CITATIONS
973	Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2007, 92, 170-175.	1.7	19
974	Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2008, 15, 101-107.	1.2	19
975	Anthracycline dose intensification in adult acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 4580-4589.	2.0	19
976	Cancer drug prices and the free-market forces. <i>Cancer</i> , 2013, 119, 3903-3905.	2.0	19
977	A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 68-72.	0.2	19
978	Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014, 167, 337-345.	1.2	19
979	Effectiveness of Homoharringtonine (Omacetaxine Mepesuccinate) for Treatment of Acute Myeloid Leukemia: A Meta-Analysis of Chinese Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 13-21.	0.2	19
980	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. <i>British Journal of Haematology</i> , 2016, 173, 114-126.	1.2	19
981	Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. <i>Cancer</i> , 2018, 124, 587-595.	2.0	19
982	Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. <i>Cancer</i> , 2019, 125, 2233-2241.	2.0	19
983	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. <i>Cancer</i> , 2020, 126, 4322-4331.	2.0	19
984	Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	2.0	19
985	A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 7012-7012.	0.8	19
986	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. <i>Leukemia</i> , 2022, 36, 257-262.	3.3	19
987	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 94.	6.9	19
988	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1733-1739.	0.6	19
989	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. <i>Cancer</i> , 2021, 127, 3552-3565.	2.0	19
990	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 286-286.	0.6	19

#	ARTICLE	IF	CITATIONS
991	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). <i>Blood</i> , 2019, 134, 290-290.	0.6	19
992	Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 83-83.	0.6	19
993	Introduction. <i>Seminars in Hematology</i> , 2007, 44, 1-3.	1.8	18
994	Novel therapies for relapsed acute lymphoblastic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 148-156.	1.2	18
995	Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2011, 96, 918-924.	1.7	18
996	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 163-168.e2.	0.2	18
997	<i>t</i> TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017, 123, 3717-3724.	2.0	18
998	Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 97-116.	0.8	18
999	Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984949.	1.1	18
1000	Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7001-7001.	0.8	18
1001	Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. <i>Blood</i> , 2020, 136, 19-20.	0.6	18
1002	A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage. <i>Blood</i> , 2014, 124, 2255-2255.	0.6	18
1003	Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7013-7013.	0.8	18
1004	Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7051-7051.	0.8	18
1005	Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. <i>Oncotarget</i> , 2019, 10, 1250-1265.	0.8	18
1006	High-Dose Cytosine Arabinoside in Chronic Lymphocytic Leukemia: A Clinical and Pharmacologic Analysis. <i>Leukemia and Lymphoma</i> , 1993, 10, 43-48.	0.6	17
1007	Topotecan in chronic lymphocytic leukemia. <i>Cancer</i> , 1995, 75, 1104-1108.	2.0	17
1008	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2005, 29, 649-652.	0.4	17

#	ARTICLE	IF	CITATIONS
1009	The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , 2008, 113, 1338-1343.	2.0	17
1010	An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. <i>Leukemia Research</i> , 2008, 32, 936-943.	0.4	17
1011	Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. <i>Cancer</i> , 2012, 118, 5819-5822.	2.0	17
1012	Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1977-1986.	0.9	17
1013	Complete Cytogenetic Response, Not Deep Molecular Response, Is Associated With Survival in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 3077-3077.	0.8	17
1014	Improvement in clinical outcome of <i>FLT3</i> ITD mutated acute myeloid leukemia patients over the last one and a half decade. <i>American Journal of Hematology</i> , 2015, 90, 1065-1070.	2.0	17
1015	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 3812-3820.	2.0	17
1016	Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. <i>Immunotherapy</i> , 2016, 8, 135-143.	1.0	17
1017	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. <i>Current Oncology Reports</i> , 2016, 18, 4.	1.8	17
1018	Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 924-928.	2.0	17
1019	Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 574-578.	1.8	17
1020	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with <i>FLT3</i> internal tandem duplication and worse relapse-free survival. <i>American Journal of Hematology</i> , 2018, 93, 1376-1383.	2.0	17
1021	NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1 mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E158-E160.	2.0	17
1022	An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E229-E232.	2.0	17
1023	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. <i>Blood</i> , 2018, 132, 553-553.	0.6	17
1024	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 18-20.	0.6	17
1025	The cure of leukemia through the optimist's prism. <i>Cancer</i> , 2022, 128, 240-259.	2.0	17
1026	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035.	2.5	17

#	ARTICLE	IF	CITATIONS
1027	Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. <i>Modern Pathology</i> , 2007, 20, 811-820.	2.9	16
1028	Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. <i>Leukemia and Lymphoma</i> , 2010, 51, 475-480.	0.6	16
1029	New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 81-91.	0.6	16
1030	Pilot Study of Bortezomib for Patients With Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 355-360.	0.2	16
1031	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. <i>Cancer</i> , 2011, 117, 5085-5093.	2.0	16
1032	Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs. <i>JAMA Oncology</i> , 2015, 1, 729.	3.4	16
1033	Chronic myeloid leukemia: sequencing of TKI therapies. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 164-169.	0.9	16
1034	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 813-820.	0.6	16
1035	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 3033-3037.	2.5	16
1036	Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2020, 95, E245-E247.	2.0	16
1037	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. <i>Modern Pathology</i> , 2020, 33, 1678-1689.	2.9	16
1038	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. <i>Clinical Cancer Research</i> , 2021, 27, 2742-2754.	3.2	16
1039	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 1494-1499.	3.3	16
1040	Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations. <i>Blood</i> , 2021, 138, 2589-2592.	0.6	16
1041	Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. <i>Mayo Clinic Proceedings</i> , 2009, 84, 161-9.	1.4	16
1042	Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2020, 136, 37-38.	0.6	16
1043	Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2020, 136, 11-13.	0.6	16
1044	Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61.. <i>Blood</i> , 2006, 108, 157-157.	0.6	16

#	ARTICLE	IF	CITATIONS
1045	Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2014, 32, 7027-7027.	0.8	16
1046	Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer, 2022, , .	2.0	16
1047	Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clinical Advances in Hematology and Oncology, 2017, 15, 266-274.	0.3	16
1048	Acute lymphoblastic leukemia with myeloperoxidase activity. , 1996, 51, 147-151.		15
1049	Therapy for elderly patients with acute myeloid leukemia. Cancer, 2007, 109, 1007-1010.	2.0	15
1050	Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer, 2009, 115, 101-106.	2.0	15
1051	Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?. Seminars in Hematology, 2010, 47, 344-353.	1.8	15
1052	The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 421-426.	0.2	15
1053	Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica, 2011, 96, 347-349.	1.7	15
1054	Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 131-138.	0.2	15
1055	Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 231-238.	0.2	15
1056	Generic imatinib " impact on frontline and salvage therapy for CML. Nature Reviews Clinical Oncology, 2016, 13, 270-272.	12.5	15
1057	Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncology, 2017, 13, 2233-2242.	1.1	15
1058	Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the <sc>DACO</sc> "16 trial. American Journal of Hematology, 2018, 93, E125-E127.	2.0	15
1059	Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 91-99.	1.2	15
1060	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer, 2021, 127, 2641-2647.	2.0	15
1061	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood, 2019, 134, 2637-2637.	0.6	15
1062	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood, 2022, 140, 285-289.	0.6	15

#	ARTICLE	IF	CITATIONS
1063	Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. <i>Cancer</i> , 1986, 58, 1603-1608.	2.0	14
1064	Apoptosis in Chronic Myelogenous Leukemia: Studies of Stage-Specific Differences. <i>Leukemia and Lymphoma</i> , 1997, 25, 121-133.	0.6	14
1065	The Usefulness of High Dose (7-10mCi) Gallium (67Ga) Scanning to Diagnose Richter's Transformation. <i>Leukemia and Lymphoma</i> , 1999, 36, 151-155.	0.6	14
1066	Treatment of Myelodysplastic Syndrome: Questions Raised by the Azacitidine Experience. <i>Journal of Clinical Oncology</i> , 2002, 20, 2415-2416.	0.8	14
1067	Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. <i>Cancer</i> , 2011, 117, 982-991.	2.0	14
1068	Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2011, 117, 5261-5270.	2.0	14
1069	Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 435-440.	0.6	14
1070	Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. <i>Haematologica</i> , 2012, 97, 235-240.	1.7	14
1071	Treatment options for chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 815-828.	0.9	14
1072	Decitabine in Older Adults With Acute Myeloid Leukemia: Why Was the Dream Broken?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1795-1796.	0.8	14
1073	Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 93-97.	0.2	14
1074	A cancer trial scandal and its regulatory backlash. <i>Nature Biotechnology</i> , 2014, 32, 27-31.	9.4	14
1075	Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 327-334.e8.	0.2	14
1076	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2016, 122, 3336-3343.	2.0	14
1077	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. <i>Cancer</i> , 2018, 124, 2561-2569.	2.0	14
1078	Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e19-e25.	0.2	14
1079	Cancer research in the United States: A critical review of current status and proposal for alternative models. <i>Cancer</i> , 2018, 124, 2881-2889.	2.0	14
1080	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. <i>Cancer</i> , 2019, 125, 3219-3224.	2.0	14

#	ARTICLE	IF	CITATIONS
1081	Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2021, 39, 2535-2538.	0.8	14
1082	Long-term results of a phase 2 trial of nilotinib 400mg twice daily in newly diagnosed patients with chronic phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 1448-1459.	2.0	14
1083	A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2018, 132, 32-32.	0.6	14
1084	Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 15-17.	0.6	14
1085	Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).. <i>Blood</i> , 2005, 106, 1831-1831.	0.6	14
1086	Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.. <i>Blood</i> , 2007, 110, 2815-2815.	0.6	14
1087	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. <i>Nature Communications</i> , 2022, 13, 2228.	5.8	14
1088	Therapy of Core Binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long-Term Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 153-158.	0.2	13
1089	Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. <i>Leukemia and Lymphoma</i> , 2013, 54, 2592-2600.	0.6	13
1090	Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. <i>American Journal of Hematology</i> , 2013, 88, 198-200.	2.0	13
1091	Inotuzumab Ozogamicin in the treatment of acute lymphoblastic leukemia. <i>Frontiers in Bioscience - Elite</i> , 2014, E6, 40-45.	0.9	13
1092	Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	13
1093	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 351-358.	2.0	13
1094	Clinical outcomes in adult patients with aplastic anemia: A single institution experience. <i>American Journal of Hematology</i> , 2017, 92, 1295-1302.	2.0	13
1095	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Haematologica</i> , 2017, 102, 1709-1717.	1.7	13
1096	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 92-99.	0.7	13
1097	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	2.0	13
1098	Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 9-11.	0.6	13

#	ARTICLE	IF	CITATIONS
1099	Clinical Relevance of CRp in Untreated AML. Blood, 2005, 106, 541-541.	0.6	13
1100	Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML).. Blood, 2007, 110, 1035-1035.	0.6	13
1101	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3721-3721.	0.6	13
1102	Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.. Journal of Clinical Oncology, 2014, 32, 7084-7084.	0.8	13
1103	inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. American Journal of Clinical Pathology, 2005, 124, 807-14.	0.4	13
1104	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology, 2022, 15, 12.	6.9	13
1105	Treatment of Relapsed or Refractory AML with Intermediate-dose Arabinosylcytosine (Ara-C): Confirmation of the Importance of Ara-C Triphosphate Formation in Mediating Response to Ara-C. Leukemia and Lymphoma, 1993, 10, 115-121.	0.6	12
1106	Deletions in the 13q14 locus in adult lymphoblastic leukemia. , 2000, 88, 1359-1364.		12
1107	Results of Therapy with Interferon Alpha and Cyclic Combination Chemotherapy in Patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Early Chronic Phase. Leukemia and Lymphoma, 2001, 41, 309-319.	0.6	12
1108	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opinion on Investigational Drugs, 2008, 17, 1127-1136.	1.9	12
1109	L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e191-e195.	0.2	12
1110	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood, 2018, 132, 36-36.	0.6	12
1111	Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 2640-2640.	0.6	12
1112	Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. Blood, 2020, 136, 33-36.	0.6	12
1113	A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.. Journal of Clinical Oncology, 2018, 36, 7041-7041.	0.8	12
1114	Phase I study of oral topotecan in hematological malignancies. Clinical Cancer Research, 2003, 9, 4084-91.	3.2	12
1115	Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia, 2022, 36, 1261-1273.	3.3	12
1116	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology, 2022, 97, 865-876.	2.0	12

#	ARTICLE	IF	CITATIONS
1117	Granulocyte-Colony Stimulating Factor, Granulocyte-Macrophage Colony Stimulating Factor, PIXY-321, Stem Cell Factor, Interleukin-3, and Interleukin-7: Receptor Binding and Effects on Clonogenic Proliferation in Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 16, 79-88.	0.6	11
1118	Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia. , 2000, 88, 570-576.		11
1119	Acute Pancreatitis Associated with Interferon Alpha Therapy for Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 39, 647-650.	0.6	11
1120	Clofarabine in Adult Acute Leukemias: Clinical Success and Pharmacokinetics. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1417-1423.	0.4	11
1121	Development and targeted use of nilotinib in chronic myeloid leukemia. <i>Drug Design, Development and Therapy</i> , 2008, 2, 233.	2.0	11
1122	Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S261-S265.	1.4	11
1123	Emerging therapy for the treatment of acute lymphoblastic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 1-11.	1.0	11
1124	The Search for Better Prognostic Models in Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 13-21.	1.2	11
1125	A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 395-400.e1.	0.2	11
1126	Contract research organizations in oncology clinical research: Challenges and opportunities. <i>Cancer</i> , 2016, 122, 1476-1482.	2.0	11
1127	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. <i>Leukemia and Lymphoma</i> , 2018, 59, 1312-1322.	0.6	11
1128	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. <i>American Journal of Hematology</i> , 2019, 94, 408-416.	2.0	11
1129	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 909-917.	0.6	11
1130	Phase II study of single-agent nivolumab in patients with myelofibrosis. <i>Annals of Hematology</i> , 2021, 100, 2957-2960.	0.8	11
1131	Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 1453-1453.	0.6	11
1132	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2647-2647.	0.6	11
1133	Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. <i>Blood</i> , 2020, 136, 43-44.	0.6	11
1134	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations. <i>Blood</i> , 2020, 136, 8-10.	0.6	11

#	ARTICLE	IF	CITATIONS
1135	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	0.6	11
1136	Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon- γ . <i>Blood</i> , 2005, 106, 1089-1089.	0.6	11
1137	A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2006, 108, 1862-1862.	0.6	11
1138	Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.. <i>Blood</i> , 2012, 120, 2630-2630.	0.6	11
1139	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 588-588.	0.6	11
1140	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 815-815.	0.6	11
1141	<scp>Freeze-dried</scp> platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. <i>American Journal of Hematology</i> , 2022, 97, 256-266.	2.0	11
1142	Time to blur the blast boundaries. <i>Cancer</i> , 2022, 128, 1568-1570.	2.0	11
1143	Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 229-234.	1.1	10
1144	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. <i>Cancer</i> , 2003, 97, 3010-3016.	2.0	10
1145	Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. <i>Leukemia Research</i> , 2004, 28, 657-660.	0.4	10
1146	The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. <i>Targeted Oncology</i> , 2006, 1, 186-196.	1.7	10
1147	Current and Future Management Options for Myelodysplastic Syndromes. <i>Drugs</i> , 2010, 70, 1381-1394.	4.9	10
1148	The Chronic Leukemias. , 2012, , 1209-1218.		10
1149	Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1985-1993.	1.2	10
1150	Cancer research in the United States: Dying by a thousand paper cuts. <i>Cancer</i> , 2013, 119, 3742-3745.	2.0	10
1151	Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 601-611.	1.4	10
1152	Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. <i>Leukemia and Lymphoma</i> , 2019, 60, 3292-3295.	0.6	10

#	ARTICLE	IF	CITATIONS
1153	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. <i>American Journal of Hematology</i> , 2019, 94, 74-79.	2.0	10
1154	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	0.6	10
1155	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e871-e882.	0.2	10
1156	Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	2.0	10
1157	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	2.0	10
1158	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021, 127, 3381-3389.	2.0	10
1159	Development of TP53 mutations over the course of therapy for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1420-1428.	2.0	10
1160	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 17-19.	0.6	10
1161	Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. <i>Blood</i> , 2020, 135, 510-513.	0.6	10
1162	Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010, 116, 656-656.	0.6	10
1163	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. <i>Blood</i> , 2020, 136, 43-45.	0.6	10
1164	Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. <i>Cancer</i> , 1991, 67, 1946-1949.	2.0	9
1165	Long-Term Follow-Up Results of Alpha Interferon Therapy in Chronic Myelogenous Leukemia at M. D. Anderson Cancer Center. <i>Leukemia and Lymphoma</i> , 1993, 11, 169-174.	0.6	9
1166	Topotecan (Hycamptin) and Topotecan-Containing Regimens in the Treatment of Hematologic Malignancies. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 247-259.	1.8	9
1167	Clinical Algorithms for the Treatment of Patients With Chronic Myeloid Leukemia: The 2010 Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S6-S13.	0.2	9
1168	Outcome of Treatment of Chronic Myeloid Leukemia With Second-Generation Tyrosine Kinase Inhibitors After Imatinib Failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S101-S110.	0.2	9
1169	Gemtuzumab ozogamicin in acute myeloid leukaemia. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 310-311.	12.5	9
1170	Current Practices in the Management of Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 48-54.	0.2	9

#	ARTICLE	IF	CITATIONS
1171	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Review of Hematology, 2016, 9, 433-445.	1.0	9
1172	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. International Journal of Hematology, 2018, 107, 689-695.	0.7	9
1173	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF- κ B activation. Leukemia Research, 2018, 73, 78-85.	0.4	9
1174	Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥ 60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica, 2018, 103, e514-e518.	1.7	9
1175	Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Advances, 2019, 3, 1533-1539.	2.5	9
1176	Impact of <i>CD33</i> and <i>ABCB1</i> single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. American Journal of Hematology, 2020, 95, E225-E228.	2.0	9
1177	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<i>MDS/MPN-rs-t</i>) and myelodysplastic syndrome with ring sideroblasts (<i>MDS-rs</i>). American Journal of Hematology, 2021, 96, E246-E249.	2.0	9
1178	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood, 2019, 134, 645-645.	0.6	9
1179	Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.. Journal of Clinical Oncology, 2013, 31, 7048-7048.	0.8	9
1180	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia, 2022, 36, 1253-1260.	3.3	9
1181	Investigational strategies in chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 619-639.	0.9	8
1182	Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Annals of Hematology, 2005, 84, 18-24.	0.8	8
1183	Clofarabine: emerging role in leukemias. Expert Opinion on Investigational Drugs, 2009, 18, 1559-1564.	1.9	8
1184	Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure. Clinical Lymphoma and Myeloma, 2009, 9, S272-S279.	1.4	8
1185	A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Investigational New Drugs, 2011, 29, 323-331.	1.2	8
1186	Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 592-596.	0.2	8
1187	Clofarabine in the treatment of myelodysplastic syndromes. Expert Opinion on Investigational Drugs, 2014, 23, 255-263.	1.9	8
1188	The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 390-394.	0.6	8

#	ARTICLE	IF	CITATIONS
1189	Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. <i>Blood Advances</i> , 2016, 1, 260-264.	2.5	8
1190	Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-acute lymphoblastic lymphoma with hyper-CVAD based regimens. <i>American Journal of Hematology</i> , 2017, 92, E595-E597.	2.0	8
1191	The many roads to universal health care in the USA. <i>Lancet Oncology</i> , The, 2019, 20, e601-e605.	5.1	8
1192	Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment. <i>Cancer Medicine</i> , 2019, 8, 5959-5968.	1.3	8
1193	The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1127-1134.	2.0	8
1194	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E50-E53.	2.0	8
1195	Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. <i>Cancer Medicine</i> , 2021, 10, 2601-2610.	1.3	8
1196	When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era. <i>Journal of Clinical Oncology</i> , 2021, 39, 3104-3108.	0.8	8
1197	Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. <i>Blood</i> , 2020, 136, 53-55.	0.6	8
1198	Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 20-22.	0.6	8
1199	Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.. <i>Blood</i> , 2004, 104, 1009-1009.	0.6	8
1200	A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.. <i>Blood</i> , 2004, 104, 1011-1011.	0.6	8
1201	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. <i>Blood</i> , 2014, 124, 4552-4552.	0.6	8
1202	Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7012-7012.	0.8	8
1203	Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 2736-2745.	2.0	8
1204	Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. <i>Lancet Haematology</i> , the, 2022, 9, e535-e545.	2.2	8
1205	Therapy of Chronic Myelogenous Leukemia with Interferon. <i>Cancer Investigation</i> , 1989, 7, 83-91.	0.6	7
1206	Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. <i>British Journal of Haematology</i> , 2004, 124, 727-738.	1.2	7

#	ARTICLE	IF	CITATIONS
1207	Chemotherapy Drug Shortages in the United States Revisited. <i>Journal of Oncology Practice</i> , 2014, 10, 329-331.	2.5	7
1208	Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. <i>Leukemia and Lymphoma</i> , 2016, 57, 654-665.	0.6	7
1209	CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. <i>Leukemia and Lymphoma</i> , 2016, 57, 1965-1968.	0.6	7
1210	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	0.6	7
1211	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. <i>Leukemia</i> , 2020, 34, 2914-2924.	3.3	7
1212	Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. <i>Blood</i> , 2018, 132, 663-663.	0.6	7
1213	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMG632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2601-2601.	0.6	7
1214	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2541-2541.	0.6	7
1215	Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome ⁺ positive (Ph ⁺) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7030-7030.	0.8	7
1216	Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML) Tj ETQq0,0,0 rgBT /Overlock 1	0.8	7
1217	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome ⁻ negative B ⁺ cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
1218	ADULT ACUTE LYMPHOCYTIC LEUKEMIA. <i>Hematology/Oncology Clinics of North America</i> , 2000, 14, 1205-1208.	0.9	6
1219	Current Perspectives on the Treatment of Patients with Chronic Myeloid Leukemia: An Individualized Approach to Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 357-365.	1.0	6
1220	Dasatinib for the treatment of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2011, 4, 253-260.	1.0	6
1221	Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 407-423.	1.0	6
1222	Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 693-699.	0.2	6
1223	Obamacare: Why Should We Care?. <i>Journal of Oncology Practice</i> , 2014, 10, 12-14.	2.5	6
1224	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. <i>Cancer Genetics</i> , 2016, 209, 205-214.	0.2	6

#	ARTICLE	IF	CITATIONS
1225	Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2020, 33, 101225.	0.7	6
1226	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis. Leukemia and Lymphoma, 2021, 62, 224-228.	0.6	6
1227	Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS.. Blood, 2007, 110, 247-247.	0.6	6
1228	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, 7539-7539.	0.8	6
1229	Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors. Blood, 2020, 136, 25-26.	0.6	6
1230	TP53 altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor based therapy: A retrospective analysis. American Journal of Hematology, 2022, 97, 1005-1012.	2.0	6
1231	Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 ⁻⁴ and higher. American Journal of Hematology, 2022, 97, 1135-1141.	2.0	6
1232	Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines. British Journal of Haematology, 1991, 78, 359-367.	1.2	5
1233	New Directions in the Biology and Therapy of Chronic Myeloid Leukemia. Leukemia and Lymphoma, 1992, 6, 89-95.	0.6	5
1234	Therapy of chronic myelogenous leukemia. Stem Cells, 1993, 11, 8-9.	1.4	5
1235	Adult Acute Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2001, 15, 207-211.	0.9	5
1236	Drug Insight: emerging new drugs in the treatment of myelodysplastic syndromes. Nature Clinical Practice Oncology, 2005, 2, 348-355.	4.3	5
1237	Optimizing Treatment with Bcr-Abl Tyrosine Kinase Inhibitors in Philadelphia Chromosome Positive Chronic Myeloid Leukemia: Focus on Dosing Schedules. Clinical Lymphoma and Myeloma, 2008, 8, S75-S81.	1.4	5
1238	Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Journal of Blood Medicine, 2015, 6, 25.	0.7	5
1239	Role of the 340B Drug Discount Program in Recent Cancer Care Trends. Journal of Oncology Practice, 2015, 11, 303-307.	2.5	5
1240	Insurance Denial of Coverage for Patients Enrolled in Cancer Clinical Trials Is Still a Problem in the Affordable Care Act Era. Journal of Oncology Practice, 2016, 12, 283-285.	2.5	5
1241	Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Lancet, The, 2016, 387, 2360-2361.	6.3	5
1242	The Affordable Care Act, or Obamacare, 3 years later: A reality check. Cancer, 2017, 123, 25-28.	2.0	5

#	ARTICLE	IF	CITATIONS
1243	Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 722-725.	0.6	5
1244	Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1665-1673.	2.0	5
1245	<i>GATA3</i> rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with <i>CRLF2</i> rearrangement and poor prognosis. <i>American Journal of Hematology</i> , 2021, 96, E71-E74.	2.0	5
1246	Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. <i>Cancer</i> , 2021, 127, 1894-1900.	2.0	5
1247	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	2.8	5
1248	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	2.0	5
1249	Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. <i>Blood Advances</i> , 2021, 5, 3913-3918.	2.5	5
1250	SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 61-66.	0.2	5
1251	Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 7-9.	0.6	5
1252	Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. <i>Blood</i> , 2020, 136, 26-28.	0.6	5
1253	Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2080-2080.	0.6	5
1254	Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2014, 124, 4558-4558.	0.6	5
1255	Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2017, 130, 886-886.	0.6	5
1256	Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (INO) in the phase 3 INO-VATE trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7013-7013.	0.8	5
1257	The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 29-36.	1.0	5
1258	Amsacrine and Continuous-Infusion High-Dose Cytosine Arabinoside as Induction Therapy for Patients with Newly-Diagnosed Acute Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 22, 71-76.	0.6	4
1259	Novel therapies for patients with chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 271-282.	1.1	4
1260	Experimental therapy in myelofibrosis with myeloid metaplasia. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1555-1563.	1.9	4

#	ARTICLE	IF	CITATIONS
1261	Management of Patients with Newly Diagnosed Chronic Myeloid Leukemia: Opportunities and Challenges. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S51-S57.	1.4	4
1262	Standard Management of Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S382-S390.	1.4	4
1263	Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 3065-3072.	0.9	4
1264	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1478-1484.	0.6	4
1265	Molecular Resistance: An Early Indicator for Treatment Change?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 79-87.	0.2	4
1266	Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 197-200.	0.2	4
1267	The Patient Protection and Affordable Care Act: Is it good or bad for oncology?. <i>Cancer</i> , 2014, 120, 1600-1603.	2.0	4
1268	Outcomes of patients with myelodysplastic syndrome and chronic myelomonocytic leukemia post clofarabine failure. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 29-34.	1.1	4
1269	Emerging drugs for acute lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 37-50.	1.0	4
1270	Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?. <i>Lancet Oncology</i> , The, 2015, 16, 1274-1275.	5.1	4
1271	Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 385-389.	2.0	4
1272	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. <i>Cancer</i> , 2017, 123, 609-616.	2.0	4
1273	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. <i>Leukemia and Lymphoma</i> , 2017, 58, 866-871.	0.6	4
1274	Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E256-E259.	2.0	4
1275	How much of US health care spending provides direct care or benefit to patients?. <i>Cancer</i> , 2019, 125, 1404-1409.	2.0	4
1276	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. <i>American Journal of Hematology</i> , 2019, 94, E188-E190.	2.0	4
1277	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline <i>RUNX1</i> mutations. <i>American Journal of Hematology</i> , 2020, 95, E313-E315.	2.0	4
1278	Clinical value of event-free survival in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1690-1699.	2.5	4

#	ARTICLE	IF	CITATIONS
1279	Type I interferon upregulation and deregulation of genes involved in monoopoiesis in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2021, 101, 106511.	0.4	4
1280	Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. <i>Current Oncology Reports</i> , 2021, 23, 95.	1.8	4
1281	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	2.0	4
1282	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. <i>Blood</i> , 2018, 132, 34-34.	0.6	4
1283	Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd. <i>Blood</i> , 2019, 134, 665-665.	0.6	4
1284	Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2011, 118, 3102-3102.	0.6	4
1285	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). <i>Blood</i> , 2013, 122, 1496-1496.	0.6	4
1286	Recent experience with decitabine in MDS. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 140.	0.3	4
1287	Idiopathic Thrombocytopenic Purpura Following Successful Treatment of Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 41, 217-220.	0.6	3
1288	Decitabine in myelodysplastic syndromes. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 835-842.	0.2	3
1289	Response: Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule. <i>Blood</i> , 2007, 110, 1083-1083.	0.6	3
1290	Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 114-119.	2.0	3
1291	Relationship Between Ruxolitinib Dose and Improvements in Spleen Volume and Symptoms in Patients With Myelofibrosis: Results From COMFORT-I. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S371-S372.	0.2	3
1292	Decitabine for the treatment of acute myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 661-673.	0.5	3
1293	Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2018, 32, 2278-2281.	3.3	3
1294	Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1012-1015.	0.6	3
1295	The “American (cancer) patients first” plan to reduce drug prices” A critical assessment. <i>American Journal of Hematology</i> , 2018, 93, 1444-1450.	2.0	3
1296	Clinical Manifestations and Treatment of Acute Myeloid Leukemia. , 2018, , 924-943.		3

#	ARTICLE	IF	CITATIONS
1297	Monoclonal antibodies in frontline acute lymphoblastic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101226.	0.7	3
1298	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. <i>British Journal of Haematology</i> , 2020, 191, e77-e81.	1.2	3
1299	The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 63-65.	0.2	3
1300	Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Clinical and Translational Science</i> , 2021, 14, 184-193.	1.5	3
1301	A new era in the treatment of acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1563-1564.	0.6	3
1302	Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2742-2748.	0.8	3
1303	Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. <i>Blood</i> , 2019, 134, 1344-1344.	0.6	3
1304	Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. <i>Blood</i> , 2020, 136, 30-33.	0.6	3
1305	Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed Disease Transformed Outcomes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 179-185.	1.8	3
1306	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2021, 13, 5607.	1.7	3
1307	Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2020, 136, 42-44.	0.6	3
1308	Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1714-1717.	0.6	3
1309	Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	3
1310	Thiotepa for the treatment of thrombocytopenia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. , 1997, 80, 396-400.		2
1311	Should oncologists support the Affordable Care Act?. <i>Lancet Oncology</i> , The, 2013, 14, 1258-1259.	5.1	2
1312	Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S289-S294.	0.2	2
1313	Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia. <i>Leukemia Research Reports</i> , 2014, 3, 17-20.	0.2	2
1314	The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015. <i>American Journal of Medicine</i> , 2015, 128, 1162-1164.	0.6	2

#	ARTICLE	IF	CITATIONS
1315	Vosaroxin: innovative anticancer quinolone for the treatment of acute myelogenous leukemia. Expert Opinion on Orphan Drugs, 2016, 4, 885-892.	0.5	2
1316	Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation, 2018, 24, S79-S80.	2.0	2
1317	Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia. , 2018, , 29-47.		2
1318	Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. American Journal of Hematology, 2018, 93, E357-E360.	2.0	2
1319	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 471-479.	0.2	2
1320	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leukemia and Lymphoma, 2019, 60, 3172-3180.	0.6	2
1321	Poor Penetration of Existing Effective Chemoimmunotherapy for the Treatment of Older Patients With Newly Diagnosed Acute Lymphocytic Leukemia (ALL) or Refractory/Relapsed ALL. Journal of Oncology Practice, 2019, 15, 77-79.	2.5	2
1322	Chronic Myeloid Leukemia. , 2020, , 1836-1849.e2.		2
1323	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American Journal of Hematology, 2020, 95, E326-E329.	2.0	2
1324	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leukemia and Lymphoma, 2021, , 1-5.	0.6	2
1325	Chronic Myelogenous Leukemia. , 0, , 76-88.		2
1326	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. Blood, 2019, 134, 2582-2582.	0.6	2
1327	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood, 2020, 136, 32-34.	0.6	2
1328	A Phase II Study of Intravenous (IV) Homoharringtonine (HHT) and Imatinib (IM) in Patients (pts) with Chronic Myeloid Leukemia (CML).. Blood, 2006, 108, 2174-2174.	0.6	2
1329	Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome.. Blood, 2007, 110, 1455-1455.	0.6	2
1330	Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia. Blood, 2013, 122, 3971-3971.	0.6	2
1331	Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood, 2015, 126, 564-564.	0.6	2
1332	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood, 2016, 128, 3171-3171.	0.6	2

#	ARTICLE	IF	CITATIONS
1333	Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.. Journal of Clinical Oncology, 2014, 32, 7031-7031.	0.8	2
1334	Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline "chemotherapy-free"™ therapy. Leukemia and Lymphoma, 2022, 63, 672-675.	0.6	2
1335	Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series. Blood, 2020, 136, 18-19.	0.6	2
1336	Improved Survival of Patients with Myelofibrosis in the Last Decade. Blood, 2020, 136, 50-51.	0.6	2
1337	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leukemia and Lymphoma, 2022, , 1-9.	0.6	2
1338	Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia. Cancer, 1988, 61, 650-653.	2.0	1
1339	Molecular approaches to the diagnosis and treatment of cancer. Stem Cells, 1993, 11, 129-130.	1.4	1
1340	Modern treatment programs for adults with acute lymphoblastic leukemia. Current Hematologic Malignancy Reports, 2007, 2, 169-175.	1.2	1
1341	New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia. Current Hematologic Malignancy Reports, 2007, 2, 183-189.	1.2	1
1342	Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia"Remarkable activity with room for improvement. American Journal of Hematology, 2008, 83, 175-177.	2.0	1
1343	Monoclonal antibodies in adult acute lymphoblastic leukemia. Hematology, 2012, 17, s52-s54.	0.7	1
1344	Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia. , 2013, , 29-44.		1
1345	Reply to price and value in cancer care. Cancer, 2015, 121, 4098-4099.	2.0	1
1346	Hepatitis C: When high drug prices preclude patient benefit. Cancer, 2018, 124, 1644-1646.	2.0	1
1347	Management of Older Patients with Acute Lymphocytic Leukemia " Novel Treatment Strategies. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S30-S31.	0.2	1
1348	Emil J. Freireich: Legend in Cancer Research (March 16, 1927 to February 1, 2021). Leukemia, 2021, 35, 1808-1811.	3.3	1
1349	Remembering Emil J Freireich: Trailblazing pioneer and giant in cancer research. American Journal of Hematology, 2021, 96, 647-649.	2.0	1
1350	ATM gene deletion in patients with adult acute lymphoblastic leukemia. , 2000, 88, 1057.		1

#	ARTICLE	IF	CITATIONS
1351	Characteristics of accelerated disease in chronic myelogenous leukemia. , 1988, 61, 1441.		1
1352	Neutrophilicâ€chronic myeloid leukemia. Cancer, 2002, 94, 2416-2425.	2.0	1
1353	Chronic Myeloid Leukemia. , 2014, , 1944-1957.e2.		1
1354	Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression. Blood, 2020, 136, 38-40.	0.6	1
1355	Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/OR FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report. Blood, 2013, 122, 2686-2686.	0.6	1
1356	Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure.. Journal of Clinical Oncology, 2015, 33, 7076-7076.	0.8	1
1357	Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis. American Journal of Clinical Pathology, 2007, 127, 642-650.	0.4	1
1358	Biology of Chronic and Acute Myeloid Leukemia. , 2008, , 371-383.		1
1359	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood, 2020, 136, 23-25.	0.6	1
1360	Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e836-e843.	0.2	1
1361	The Role of Imatinib in the Treatment of Chronic Myelogenous Leukemia. American Journal of Cancer, 2004, 3, 337-348.	0.4	0
1362	Optimal Therapy for Chronic Myeloid Leukemia Blast Crisis: Current Concepts. Clinical Leukemia, 2006, 1, 87-94.	0.2	0
1363	Challenges and Progress in the Treatment of Adults with Philadelphia Chromosomeâ€Positive Acute Lymphoblastic Leukemia. Clinical Leukemia, 2006, 1, 19-27.	0.2	0
1364	The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. Leukemia and Lymphoma, 2007, 48, 802-804.	0.6	0
1365	Introduction: Targeting Different Pathways to Prevent Tumor Cell Development. Seminars in Oncology, 2009, 36, S1-S5.	0.8	0
1366	Molecular pathology of leukemia. , 0, , 1-25.		0
1367	Applying Cytogenetic and Molecular Information in the Clinic: Implications for the Treatment of Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S14-S19.	0.2	0
1368	Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Opinion on Orphan Drugs, 2013, 1, 607-623.	0.5	0

#	ARTICLE	IF	CITATIONS
1369	Novel treatment options for acute myelocytic leukemia. <i>Clinical Investigation</i> , 2013, 3, 979-990.	0.0	0
1370	Meir Wetzler, MD. <i>Cancer</i> , 2015, 121, 2106-2107.	2.0	0
1371	In Response to S.A. Glied. <i>Journal of Oncology Practice</i> , 2015, 11, 166-166.	2.5	0
1372	Treatment of Adult Acute Lymphocytic Leukemia (ALL) in 2017. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S57-S60.	0.2	0
1373	Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 347-356.	1.1	0
1374	Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?. <i>Cancer</i> , 2018, 124, 4261-4261.	2.0	0
1375	Reply to Miniâ€HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. <i>Cancer</i> , 2019, 125, 3891-3892.	2.0	0
1376	Blinatumomab for the treatment of acute lymphoblastic leukemia: an update. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 41-46.	0.5	0
1377	CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. <i>Hematologic Malignancies</i> , 2021, , 61-76.	0.2	0
1378	Honoring Emil J. Freireich: A Visionary Medical Cancer Researcherâ€”March 21, 1927â€”February 1, 2021. <i>Blood Cancer Discovery</i> , 2021, 2, 190-191.	2.6	0
1379	Emil J. Freireich 1927â€”2021. <i>Nature Cancer</i> , 2021, 2, 251-252.	5.7	0
1380	Emil J. Freireich: Legend in cancer research (March 16, 1927â€”February 1, 2021). <i>Bone Marrow Transplantation</i> , 2021, 56, 1764-1767.	1.3	0
1381	Hyper-CVAD in 2021: Lessons Learned and New Approaches. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S82-S84.	0.2	0
1382	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. , 2011, , 233-255.		0
1383	Decitabine in myelodysplastic syndromes. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 835-842.	0.2	0
1384	Frontline Therapy of Newly Diagnosed Acute Lymphoblastic Leukemia. <i>Hematologic Malignancies</i> , 2021, , 169-184.	0.2	0
1385	Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. <i>Hematologic Malignancies</i> , 2021, , 205-218.	0.2	0
1386	Management of Relapsed/Refractory Acute Myeloid Leukemia. <i>Hematologic Malignancies</i> , 2021, , 89-109.	0.2	0

#	ARTICLE	IF	CITATIONS
1387	Baseline Mutations Lack Impact on Clinical Outcomes and Molecular Response in Core Binding Factor Leukemia Treated with Highly Effective Regimen. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
1388	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
1389	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 39-41.	0.6	0
1390	Diploid Karyotype Represents a Favorable Prognostic Subgroup in Blast Phase Myeloproliferative Neoplasms. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
1391	Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. <i>Blood</i> , 2020, 136, 28-29.	0.6	0
1392	Outcomes of Patients with Myelofibrosis and Favorable Karyotype. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
1393	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 45-47.	0.6	0
1394	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2020, 136, 36-38.	0.6	0
1395	Characteristics and Outcome of Myelofibrosis Patients on Long-Term Ruxolitinib Therapy (≥3 years). <i>Blood</i> , 2020, 136, 19-20.	0.6	0
1396	Prediction for sustained deep molecular response for treatment-free remission. <i>Leukemia and Lymphoma</i> , 2022, 63, 5-6.	0.6	0
1397	Management of acute myeloid leukemia. , 0, , 26-42.		0
1398	Treatment of acute lymphoblastic leukemia (ALL) in adults. , 2010, , 43-67.		0
1399	Chronic myeloid leukemia. , 0, , 68-80.		0
1400	Myelodysplastic syndromes (MDS). , 0, , 103-115.		0
1401	Burkitt lymphoma. , 0, , 494-502.		0